Tianjin Medical University Cancer Hospital

Medical Oncology Department›

The Department of Medical Oncology of Tianjin Medical University Cancer Hospital is a professional clinical department focusing on chemotherapy, endocrine therapy, and immunotherapy of malignant tumors. There are currently 9 professional and technical personnel, including 1 chief physician and professor; There are 3 deputy chief physicians. Responsible for the training and teaching of postgraduate students majoring in medical oncology, there are currently 4 postgraduate students. The department has 65 inpatient beds and 3 laminar flow purification ward beds. View full introduction

Hematology Department›

The Department of Hematology of Tianjin Medical University Cancer Hospital is a hematology specialty established in a large cancer center. The disciplinary medical teaching and research have been comprehensively developed, and the clinical scientific research level ranks among the top in the country. It has become one of the training centers for blood diseases, especially blood cancer diagnosis and treatment, scientific research and specialist technical personnel in North China. Founded in 2008, Director Da Wanming, a first-level professor of the Chinese People's Liberation Army, provided strong technical support as an honorary professor in the early days of the establishment of the department. Based on Tianjin Medical University, the Department of Hematology is a distinctive and advantageous discipline in China that can simultaneously carry out multiple methods of diagnosis of blood diseases (cell, immune, molecular biology, cytogenetics, etc.) and multi-level systematic treatment (chemotherapy, hematopoietic stem cell transplantation). It mainly treats various blood tumors such as leukemia, lymphoma, multiple myeloma, etc., and also provides consultation and technical support for coagulation and anemia diseases for various majors in the tumor center. The department currently has 16 doctors (including one examining doctor) and 34 nurses. The doctors include 3 with senior professional titles, 7 with associate senior professional titles, and 3 with intermediate professional titles; 1 doctoral supervisor and 5 master's supervisors; 12 have doctoral degrees and 3 have master's degrees. Physicians in the department serve as members of the Standing Committee of the Hematology Oncology Committee of the Chinese Anti-Cancer Association, the Standing Committee of the CSCO China Anti-Lymphoma Alliance, the Multiple Myeloma Professional Committee of the Chinese Medical Doctor Association, the Vice Chairman of the Hematology Oncology Committee of the Tianjin Anti-Cancer Association, the Vice President of the Hematology Society of the Tianjin Medical Doctor Association, the Chairman of the Geriatric Oncology Committee of the Tianjin Anti-Cancer Association, the corresponding editorial board member of the "Chinese Journal of Hematology", the editorial board member of the "Chinese Journal of Clinical Oncology", the editorial board member of the "Chinese Journal of Experimental Hematology", and the review expert of the National Natural Fund. The department has hosted and participated in a number of key research projects in recent years. Participated in many research projects such as the National 863 Program and major national science and technology projects. As the first person in charge, he presided over 14 National Natural Science Foundation projects, 4 Tianjin Natural Science Foundation general projects, 3 international cooperation projects, and multiple bureau-level, school-level, and college-level projects. Many doctors have been selected into the Tianjin Municipal Education Commission’s Young and Middle-aged Innovative Talents Program, Tianjin 131 Talents at All Levels, Tianjin Medical University New Century Talents, Tianjin Cancer Hospital Young and Middle-aged Leading Talents, Tianjin Cancer Hospital New Century Visitors, Tianjin Cancer Hospital “13th Five-Year Plan” Young Talents and other talent projects. At present, the total research funding of the whole department is nearly 10 million yuan. The corresponding author and first author of the whole department have published more than 200 Chinese and English papers, including more than 80 SCI articles, including 4 articles with an impact factor of 10 or above such as "leulemia". He has participated in the compilation of many Chinese and English monographs such as "Hematologic cancers: from molecular pathobiology to targeted therapeutics", "Modern Hematology", "Hematology - Continuing Medical Textbook of the Chinese Medical Association", "Leukemia", "Leukocyte Diseases - Basics and Clinics", "Rational Use of Drugs in Hematology (Second Edition)", "Diagnosis and Treatment Strategies of Hematology", "Hematology Volume of Difficult Cases of Internal Medicine". The Department of Hematology is at the leading level in the country in the diagnosis and treatment of hematological tumors, translational medical research, and hematopoietic stem cell transplantation technology. The diagnosis and treatment model is in line with international standards, and it fully adopts cell morphology/cytochemistry, multi-parameter flow cytometry, karyotype analysis, molecular genetics, molecular biology and other technologies. Surgery is combined with clinical diagnosis, classification, prognosis assessment and condition monitoring, and an individualized treatment plan is customized for the patient. It uses combined chemotherapy, radiotherapy, immunotherapy, molecular targeted therapy, hematopoietic stem cell transplantation and other methods to treat tumors, significantly extending the patient's survival time and improving the patient's quality of life. Ward construction: The hematology ward is divided into 3 wards with a total of 56 beds, including 6 100-level laminar flow wards (transplant cabins), and the branch hospital has more than 20 beds. At present, focusing on hematological malignant diseases such as leukemia, lymphoma, myeloma, and myelodysplastic syndrome, we have established and improved a stratified treatment system for various hematological tumors, and carried out hematopoietic stem cell transplantation for benign and malignant hematological diseases. More than 300 transplants have been completed so far. The autologous stem cell transplantation work led by Academician Hao Xishan won the first prize of the Chinese Medical Award. At the same time, in cooperation with the Department of Children's Oncology, more than 70 cases of stem cell transplantation treatment of children's solid tumors were successfully carried out and achieved good results. Since its founding, the company has led or participated in more than 20 international and domestic multi-center clinical studies. The Hematology Department of Tianjin Medical University Cancer Hospital opened the "Multiple Myeloma Joint Clinic" in 2013. Led by the Department of Hematology, it is jointly consulted with senior experts from the Department of Osteosoft Oncology, Pathology, Integrated Traditional Chinese and Western Medicine, Radiation Therapy, and Radiology, taking advantage of the complementary advantages of multiple disciplines to make a comprehensive and accurate diagnosis for the patient and formulate an individualized treatment plan. Since the opening of the multiple myeloma joint clinic, good clinical results have been achieved. Carry out long-term exchanges and cooperation with many well-known foreign cancer centers. Many doctors have gone to the above-mentioned units for further clinical studies or postdoctoral training, and have achieved fruitful results. At the same time, a remote consultation system has been established with them to bring the clinical and scientific research of the hematology department into line with the world. A number of international cooperations have been carried out in clinical trials of new anti-cancer drugs, exchange of experiences on difficult cases, and training of technical personnel. The department holds a hematological tumor forum that radiates surrounding provinces and cities every two to three months, and has been held for more than 20 times so far. The National Summit Forum is held every year, a total of 4 times, and the International Hematology Summit Forum is 1. It has carried out multi-disciplinary exchanges and inter-academic discussions on hematological tumor-related diseases many times, and invited 10 foreign experts including Chairman of the Chinese Anti-Cancer Association and Academician of the Chinese Academy of Engineering Hao Xishan, Academician Ruan Changgeng of the Chinese Academy of Engineering, and Academician Wu Zuze of the Chinese Academy of Sciences to attend the meeting. Through a combination of theoretical lectures and discussions, we will teach the international diagnosis and treatment standards in the field of hematological tumors as well as new theories, new knowledge, new technologies, and new methods in recent years to young doctors working in front-line clinical and scientific research positions, so that our professional and technical personnel can continuously improve their professional level and service quality to adapt to the development of medical science, technology, and health undertakings. We have held many regional academic activities covering the surrounding areas and regular patient exchange meetings to answer patients' questions about their personal difficulties. Actively cultivate amphibious talents with both clinical and scientific research capabilities, and provide strong support in terms of direction, personnel, and funding based on their strengths and interests. Eight doctors have been selected and sent to authoritative foreign institutions for postdoctoral research or clinical training. To date, the department has trained more than 50 graduate students and graduated more than 30 graduate students, 5 of whom have won national scholarships. Taught more than 10 advanced students. Professional advantage technology The Department of Hematology focuses on blood tumors and hematopoietic stem cell transplantation, and has a high academic status and influence in the country. Lymphoma direction: It is an important lymphoma diagnosis and treatment center in China. For refractory and relapsed B lymphocyte malignant lymphoma, the established prognostic stratification and individualized treatment system has been promoted in many secondary and tertiary hospitals across the country, significantly improving the clinical remission rate of patients. This part of the work won the second prize of the 2016 Chinese Anti-Cancer Association Science and Technology Progress Award. Multiple myeloma direction: Every year, more than 100 multiple myeloma patients are treated, mainly from Northeast China, North China, Inner Mongolia and other regions. The patients are managed throughout the entire process including maintenance treatment, reaching the leading level in the country. In 2013, the "Multiple Myeloma Joint Clinic" was opened. Led by the Department of Hematology, it combines simultaneous consultations with senior experts from the Department of Osteosoft Oncology, Department of Pathology, Department of Integrated Traditional Chinese and Western Medicine, Department of Radiotherapy, and Department of Radiology to leverage the complementary advantages of multiple disciplines to make a comprehensive and accurate diagnosis of the patient, formulate an individualized treatment plan, and achieve good clinical results. We also conducted a multi-center, prospective clinical trial on whole-body low-dose CT detection of multiple myeloma at different diagnosis and treatment points. This trial was funded by Tianjin Medical University Cancer Hospital. His clinical experience in the treatment of extramedullary multiple myeloma has been published in several SCI articles, and he won the second prize of the 2016 Chinese Anti-Cancer Association Science and Technology Progress Award at the same time as his diagnosis and treatment of lymphoma. Direction of hematopoietic stem cell transplantation: The autologous stem cell transplantation work led by Academician Hao Xishan won the first prize of the Chinese Medical Award. To date, more than 500 cases of various types of hematopoietic stem cell transplants have been completed, and the number of various types of transplants is steadily increasing every year. In cooperation with the Department of Children's Oncology, we are the first in China to carry out hematopoietic stem cell transplantation for children's tumors such as neuroblastoma, rhabdomyosarcoma, etc., which has significantly improved the prognosis of patients, and leads the country in the number of transplants. The results of an improved pretreatment regimen for double-hit lymphoma and other internationally recognized lymphomas with extremely poor prognosis were published in the "Chinese Journal of Hematology". Relevant clinical data are still accumulating, and it is expected to find an effective treatment approach to improve the survival of patients with this type of lymphoma. Clinical trials: As PI, he has led or participated in more than 20 international and domestic multi-center clinical studies. Clinical trials he presided over: Randomized, open-label, positive-drug parallel-controlled, multi-center clinical trial of recombinant human erythropoietin (CHO cells) for injection in the treatment of anemia caused by chemotherapy of non-bone marrow malignancies (clinical trial number: BOJI201716Q), and led two other clinical trials initiated by researchers. View full introduction

Department of Digestive Oncology›

The Department of Gastroenterology and Oncology of Tianjin Medical University Cancer Hospital is one of the earliest specialized cancer departments established in China, focusing on the diagnosis, treatment and basic research of digestive system tumors. Professor Bayi, the subject leader, adheres to the concept of international standardized diagnosis and treatment and has established a professional and intensive digestive system tumor diagnosis and treatment team, dedicated to providing standardized professional treatment and unique individualized treatment to the majority of patients. We have accumulated rich experience in the adjuvant treatment and neoadjuvant treatment of malignant tumors of the digestive tract (including esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver and biliary system tumors, gastrointestinal stromal tumors, neuroendocrine tumors, etc.), as well as drug therapy (chemotherapy, targeted therapy and immunotherapy), comprehensive treatment and individualized treatment for patients with advanced tumors. The treatment level is in the leading position in the country and has become a well-known professional team for digestive tract tumors in the country. The department currently has 65 fixed beds, more than 30 medical staff, and receives nearly 20,000 patients every year. Patients come from all over the country and at home and abroad. The department has developed rapidly since its establishment and has strong professional and technical strength. It consists of a team of young and middle-aged key doctors with an active academic atmosphere, including 10 with doctorate degrees and 4 with master's degrees; There are 1 professor/chief physician, 3 associate professors/deputy chief physicians, 5 attending physicians, and 4 resident physicians. The department attaches great importance to talent cultivation and participates in large-scale international and domestic oncology academic conferences every year. It regularly selects team members to study and visit well-known foreign cancer centers to continuously improve the professional level of team members. The department actively promotes multidisciplinary comprehensive treatment of digestive system tumors and takes the lead in carrying out MDT (multidisciplinary collaboration) comprehensive diagnosis and treatment in Tianjin, promoting the standardization process of digestive system tumor treatment in Tianjin. At the same time, on the basis of daily clinical work, the department undertakes a large amount of clinical research work on new anti-tumor drugs every year. In the past five years, it has designed, undertaken and participated in more than 40 national and global multi-center clinical studies, in order to provide more treatment options and greater survival benefits for cancer patients. As a training center for doctoral and master's students of Tianjin Medical University, the Department of Gastroenterology and Oncology is responsible for teaching doctoral students, master's students and international students. It currently has 1 doctoral supervisor and 2 master's supervisors. It trains several oncology professionals for oncology specialties across the country every year, and attracts a large number of oncology specialists from all over the country to come for further study. Professor Bayi, the subject leader, has been rated as a "New Century Talent" by the Ministry of Education, a "National Talent" by the Ministry of Human Resources and Social Security, a Tianjin 131 Innovative Talent, a leading scientific and technological talent in Tianjin Cancer Hospital, and enjoys special allowances from the State Council. As a member of the Colorectal Cancer Diagnosis and Treatment Pathway Development Committee of the Department of Medical Affairs of the Ministry of Health, Professor Ba participates in the revision of international and domestic diagnosis and treatment standards for colorectal cancer every year. In recent years, he has led the department team to obtain more than 10 national, provincial and ministerial-level projects, and published more than 50 SCI papers as the corresponding author in high-level international authoritative academic journals such as Nature Communications and CLINICAL CHEMISTRY. As the first completer, he led the team to win scientific research awards such as the Chinese Anti-Cancer Association Science and Technology Award, the Chinese Medical Science and Technology Award, the Chinese Medical Science and Technology Award, and the Tianjin Science and Technology Progress Award, etc., making important contributions to promoting the development of clinical diagnosis and treatment of digestive tract tumors and basic translational research. The digestive oncology team adheres to the "patient-centered" concept, works together and strives to provide enthusiastic help and professional and standardized treatment to every patient who comes for treatment. View full introduction

Medical Lymphoma›

The Department of Lymphoma Medicine at Tianjin Medical University Cancer Hospital is a professional discipline in a tertiary-level hospital that integrates medical treatment, teaching, scientific research, and clinical translational medicine. It has rich clinical experience in the diagnosis and treatment of lymphatic system tumors. In 2017, the number of outpatient visits exceeded 18,187. The annual outpatient visits and the number of admissions and admissions rank among the top lymphoma specialties in the country. The predecessor of the Department of Lymphoma Medicine was the Department of Chemotherapy established in 1978. In the 1970s, Professor Jin Xianzhai, the founder of oncology in my country, established a professional chemotherapy group. It was on this basis that the Department of Chemotherapy gradually developed and expanded. In 1998, the Department of Internal Oncology, now the Department of Lymphoma, was officially established. Currently, the department has a total of 93 beds, including 58 in the main ward, 16 in senior wards, and 19 in comprehensive wards; There are 21 physicians in total, including 2 chief physicians, 4 deputy chief physicians, 11 attending physicians, and 4 residents. Among them, 16 have doctorate degrees, 8 have overseas study experience, and 1 is a specially appointed lecture professor in Tianjin. Clinical diagnosis and treatment and new technologies: The diagnosis and treatment model of lymphoma medicine is in line with international standards. It comprehensively uses cell morphology/cytochemistry, karyotype analysis, molecular genetics, molecular biology and other technologies combined with clinical diagnosis, classification, prognosis assessment and disease monitoring to tailor individualized treatment plans for patients. Chemotherapy, immunotherapy, molecular targeted therapy, radiotherapy and other means are combined to treat lymphoma. Clinical, pathology, imaging, radiotherapy, biological therapy, and multidisciplinary MDT consultation in the hospital enable lymphoma patients to receive more accurate diagnosis and more standardized treatment, significantly extending the patient's survival time and improving the patient's quality of life. The new technologies currently developed by the department include: CAR-T cell therapy technology, lymphoma circulating tumor DNA (ctDNA) detection technology, etc. Lymphoma Medical Patient Education Meeting Scientific research and external exchanges: Since 2016, it has won 4 National Natural Science Foundation of China bids and has a total of 7 National Natural Science Foundation projects under research; Published 13 SCI papers, including 2 SCI papers published by the corresponding author unit with IF>10 points, 1 with IF>5 points, and 2 SCI papers with 5>IF>3 points. The number of new international and domestic clinical research projects launched in 2017 ranks first among all departments in our hospital. The department edits and publishes academic and popular science books: it participates in organizing the compilation of "Lymphoma Diagnosis and Treatment", "Cancer Prevention, Treatment and Rehabilitation", etc. In 2016, it won the third prize of Tianjin Science and Technology Progress Award. In recent years, our department has carried out long-term exchanges and cooperation with many well-known foreign cancer centers, and has sent many doctors abroad for clinical studies or scientific research training, and has achieved fruitful results. Academic conference: Relying on a professional multidisciplinary diagnosis and treatment team, the biennial Tianjin International Lymphoma Summit Forum was held in 2016, forming Tianzhu’s international lymphoma conference brand and increasing the department’s influence and visibility at home and abroad. The 2017 Tianjin How I Treat and Lymphoma Translational Medicine International Symposium provides domestic lymphoma doctors with basic and clinical research cutting-edge that is both professional and practical. In 2016, he took the lead in establishing the Lymphoma Professional Committee of the Tianjin Anti-Cancer Association and held more than 40 offline meetings with surrounding areas, including the Tianjin International Lymphoma Summit Forum, the Tianjin-Hebei Lymphoma MDT, and the Young Physician Training Course, etc., to drive the surrounding areas to jointly improve the level of lymphoma diagnosis and treatment. In 2017, the North China Lymphoma Collaboration Platform was established, linking 9 centers including Tianjin, Hebei, Shanxi, Inner Mongolia, and Shandong to initiate online and offline MDT case discussions and mutual cooperation in multi-center clinical trials and basic scientific research. The influence of Tianzhuang Lymphoma Department has gradually increased, and it has gradually developed into one of the most influential lymphoma diagnosis and treatment centers in northern China. View full introduction

Intensive Care Department›

The Intensive Care Department of Tianjin Medical University Cancer Hospital was established on April 2, 2007. It currently has 11 medical staff: 1 chief physician, 2 deputy chief physicians, 2 doctors, and 7 masters. With the development and progress of medicine, cancer is no longer an incurable disease. The diagnosis and treatment methods of cancer are changing with each passing day. Oncology critical care medicine should also keep pace with the times to protect various oncology clinical disciplines, reduce non-tumor mortality, and improve the quality of medical care and patients' quality of life. Over the past ten years since its establishment, the Oncology Intensive Care Department of our hospital has gradually built an excellent oncology critical care medical care team with a reasonable echelon of medical staff, superb skills, and outstanding treatment capabilities. It has gradually formulated a set of clinical treatment and nursing management standards for patients with severe tumors. The professional and technical capabilities of critical care medicine are not inferior to the level of domestic tertiary-level hospitals, and it also has distinctive features of critical tumors. The Intensive Care Department carries out routine intensive care and organ support technology in the ICU. It also carries out non-invasive and minimally invasive hemodynamic monitoring and treatment based on the characteristics of tumor patients, bundled strategies to prevent and control hospital-acquired infections, analgesia-based titrated sedation therapy, nutritional therapy for severe tumors and other core technologies. It actively participates in various oncology clinical disciplines to carry out MDT diagnosis and treatment work, escorts patients with severe tumors, smoothly survives the peri-tumor treatment period, improves medical quality and ensures medical safety. At the same time, as the intensive care department of the cancer hospital, it is also responsible for hospital-wide infection prevention and control, rational application of antibiotics, and emergency support for public health emergencies. At the same time, the ICU ward is constructed and configured in accordance with relevant national standards. Each bed unit is equipped with monitoring instruments and equipment. The wards are regionally arranged, including critical rescue units, intensive care units, negative pressure isolation units, VIP units, etc. to meet the treatment needs of different patients. Key physicians at all levels in the department are responsible for completing bureau-level, school-level, and hospital-level projects in their profession, leading 2 clinical trials, and publishing dozens of articles in SCI, Chinese and core journals. Participated in authoring 2 books. In the past three years, the department has hosted 3 national academic conferences on severe oncology, all of which have been well received by fellow experts and participants. Wang Donghao, the subject leader of the department, serves as the elected chairman of the Oncology Critical Care Professional Committee of the Chinese Anti-Cancer Association. At the same time, the backbone of the department holds positions in the Critical Care Medicine Branch of the Chinese Medical Association, the Enteral and Parenteral Nutrition Branch, the Tianjin Medical Association, the Physician Association, and the Anti-Cancer Association. The department continues to consolidate its professional foundation, promote the spirit of craftsmanship, and build a professional team that dares to take on responsibilities and is able to take on responsibilities. Under the leadership of Director Wang Donghaoke, the Intensive Care Department practices "two studies and one action", continuously strengthens work style construction, thoroughly implements the spirit of the 19th National Congress of the Communist Party of China, and takes protecting people's health as the goal of professional development. Three comrades from the department have won the Tianjin May 1st Labor Medal, two comrades have been awarded the title of "Good Doctor" and "Good Nurse" by the Tianjin People's Satisfaction, and many key nurses have achieved excellent results in the Tianjin Nursing Skills Competition. The department has successively won the titles of Tianjin Medical University’s Advanced Grassroots Party Organization, Youth Civilization Number, Faculty Pioneer Number, Party Member Pioneer Post, Advanced Party Organization, Advanced Collective with Noble Medical Ethics, and has been awarded the title of Five-Star Department for many consecutive years. It has won high praise and trust from the hospital, society and the people. View full introduction

Clinic Emergency Department›

The outpatient emergency department of Tianjin Medical University Cancer Hospital was established in April 1997. It is a second-level department and is under the leadership of the outpatient office. It consists of emergency observation ward and outpatient chemotherapy room. It is located in Areas D and C on the first floor of the outpatient building, covering an area of ​​about 600 square meters. Business distribution: The outpatient and emergency department consists of the following parts: 1. Treatment and observation of acute comorbidities of various tumor patients. 2. Outpatient chemotherapy room. 3. Bladder instillation. 4. Outpatient injection room. 5. Outpatient dressing room. Nature of work: Emergency patients receive basically perioperative complications, complications of radiotherapy and chemotherapy, observation and treatment of complications after minimally invasive treatment. The work mainly focuses on gastrointestinal bleeding, hemoptysis, intestinal obstruction, pleural effusion, pericardial effusion, respiratory failure, multiple organ failure, various infections, pathological fractures, low whole blood levels after chemotherapy, various shocks and treatment of chemotherapy reactions. After stabilization in the emergency department, transfer to various wards or discharge from the hospital were the main outcomes. The work specifications of this department stipulate that the department will be on duty 24 hours a day. In case of emergencies, treatment should be started within 5 minutes. For difficult and complex diseases, superior doctors should be consulted in a timely manner so that the patients can be properly handled. Various consultations in the hospital are completed within 20 minutes. When there are no outpatient clinics on holidays, emergency doctors carefully receive patients and their families who come for consultation and medicine, and explain the work patiently and meticulously. Treat patients seriously and do not shirk patients. Ensure that the life green channel is fully open 24 hours a day. The outpatient chemotherapy room uses an integral infusion track, and decorations are installed on the walls to create a warm treatment environment. It is also equipped with 2 VCD players and 2 TV sets. It cooperates with the nursing staff to provide health education to patients, plays light music intermittently, and uses music therapy to cooperate with chemotherapy, allowing patients to receive treatment in a relaxed and pleasant environment. Make the key contents of health education into a large format and hang it on the wall of the waiting area to facilitate the reading of patients and their families. In terms of scientific research: In 1997, a new technology was completed, namely "new dosage form of Rutong Capsule and clinical efficacy observation", filling the gap in the hospital. In 2002, he participated in the preparation of "Abdominal Oncology" edited by Professor Hao Xishan, and participated in the bureau-level scientific research project "Research on the Sensitization Effect of Hyperthermia on Tumor Radiotherapy and Chemotherapy". Since 1997, it has published 9 papers in national core journals, 2 papers at international conferences, and 1 paper at the Tianjin Nursing Association Annual Academic Conference. View full introduction

Anesthesiology Department›

The development of the Anesthesiology Department of Tianjin Medical University Cancer Hospital began in 1959, with the late Director Zhang Chongguang starting to study and carry out anesthesia work. In 1961, the hospital established an anesthesia team, which was subordinate to the surgical management. In 1978, the anesthesia team was officially transformed into a secondary clinical discipline and carried out general anesthesia, spinal anesthesia, nerve block and acupuncture combined anesthesia for adults and children. The anesthesiology department currently has 75 medical staff, including 64 anesthesiologists and 11 anesthetists. Among them, there is 1 doctoral supervisor, 2 master's supervisors, 15 with doctoral degrees, 32 with master's degrees, and more than 10 people have overseas clinical specialist, visiting or postdoctoral training experience. After more than 60 years of development, the Department of Anesthesiology has continued to grow under the leadership of successive department directors, Director Zhang Chongguang, Director Gao Lubo, Director Li Jincheng, Director Zhao Hongwei, and Director Yin Yiqing, and has made great progress in clinical work, scientific research and teaching. The Department of Anesthesiology completes more than 36,000 anesthesia cases in various operating rooms of the hospital every year, and more than 4,000 anesthesia cases outside the operating room for painless gastroenteroscopy and treatment, interventional treatment and other surgeries and examinations. It also excellently completes various tasks of aiding Xinjiang, Tibet and fighting the epidemic. The Anesthesiology Department has established a postoperative recovery room since 2012, and currently has 36 beds, fully meeting the needs of patients for postoperative recovery. In 2019, an anesthesia clinic was opened to provide perioperative education, evaluation and other medical services. In addition, the anesthesiology department is also responsible for the rescue and intubation work of all departments in the hospital, playing an indispensable role in the first aid of critical patients. In recent years, the Department of Anesthesiology has continuously strengthened management and improved its clinical business capabilities, actively cooperated with the needs of various surgical departments, and developed and progressed together with the Department of Surgery. In clinical work, clinical technologies such as visual endotracheal intubation and anesthesia depth monitoring in all operating rooms have been implemented, and precise anesthesia technologies such as perioperative coagulation function monitoring, cardiac output monitoring (FloTrac), muscle relaxation monitoring, closed-loop target-controlled infusion, and infusion warming have been carried out. Especially with the rise and development of enhanced recovery surgery (ERAS) and day surgery, the anesthesiology department has actively carried out various nerve block techniques such as ultrasound-guided transversus abdominis plane block (TAP), paravertebral nerve block, brachial plexus block, and thoracic nerve block, which have improved the postoperative analgesia for patients, reduced the adverse reactions of postoperative nausea and vomiting, and thus better promoted the postoperative recovery of patients. In addition, the Department of Anesthesiology has accumulated rich experience in disciplinary features such as difficult airway management, ultrasound-guided nerve block, single-lung management in thoracic surgery, anesthesia for robotic surgery, pheochromocytoma surgery, and anesthetic management of pediatric and elderly patients with severe tumors. In terms of scientific research, the Department of Anesthesiology currently undertakes 7 National Natural Science Foundation projects, 1 project each from the Ministry of Human Resources and Social Security and the Central Ministry of Health, 2 provincial and ministerial-level projects, and a number of bureau-school-level, college-level and horizontal projects under research and completed. He has conducted in-depth research on perioperative cognitive dysfunction and organ protection, research on the mechanisms of cancer pain, and the effects of anesthesia on tumor metastasis, recurrence, and hyperalgesia. The department has published more than 50 academic articles of various types in the past five years, and more than 30 articles have been included in SCI. In terms of teaching, the Department of Anesthesiology is the internship unit for postgraduate and undergraduate students of Tianjin Medical University's anesthesia major. It also accepts the study and training of anesthesiologists from all over the country. As a member of the Cancer Anesthesia and Analgesia Professional Committee of the Chinese Anti-Cancer Association, the Department of Anesthesiology is in line with international standards and has held many municipal academic conferences and training courses to provide a good academic platform for the professional development of tumor anesthesia and analgesia. In recent years, the Department of Anesthesiology has sent medical staff, mainly young doctors, to study and exchange abroad many times. Currently, there are many doctors in the department serving in different academic groups, which has established a good platform for expanding the influence of the department. The subject leader, Director Yin Yiqing, is currently a member of the Standing Committee of the Thoracic Anesthesia Branch of the Chinese Society of Cardiothoracic and Vascular Anesthesia, a national member of the Non-cardiac Surgery Anesthesia Branch of the Chinese Society of Cardiothoracic and Vascular Anesthesia, a member of the Anesthesiology Professional Committee of the Beijing Oncology Society, and a scientific and technological expert of the Beijing Municipal Science and Technology Commission. "Safety, harmony, rigor, and innovation" are the purposes of the cultural construction of the anesthesiology department. The department always stays true to its original intention and mission, leads the development of the department, and creates a good working atmosphere in the department. In the star service selection, the Anesthesiology Department has been rated as the hospital's annual five-star department for many consecutive years. At the same time, the vanguard party members of the Department of Anesthesia took the lead in setting an example and played an exemplary and leading role in all the work of the department. Directors of the Department of Anesthesiology, including Li Jincheng, Ma Changqing, Wang Weihang, Zhang Fengwen, Guo Bing, Yang Shaoyong, Xu Kuibin, and Guo Dongyong, have been recognized and praised by many parties for their dedication and dedicated service to patients in the special work of aiding Xinjiang, Tibet, and fighting SARS. In the new era and new look, the Anesthesiology Department of Tianjin Medical University Cancer Hospital will continue to develop, improve, and grow, and continue to work hard to move forward. Focusing on the overall reform and development of our hospital, we will actively promote various tasks, make greater contributions to the development of the hospital, and protect the perioperative safety of patients. View full introduction

Thyroid and Neck Tumor Department›

The Department of Thyroid and Neck Oncology of Tianjin Medical University Cancer Hospital is a professional department developed and established on the basis of the head and neck tumor professional treatment group established earlier in my country. It is currently the seat of the head and neck tumor chairman unit and secretariat of the Chinese Anti-Cancer Association, the secretariat of the Thyroid Cancer Professional Committee of the Chinese Anti-Cancer Association, and the chairman unit and secretariat of the Tianjin Thyroid Cancer Professional Committee. The founder of the discipline is Professor Li Shuling, a famous academic leader in head and neck cancer in my country. The subject leader, Professor Gao Ming, is a doctoral supervisor. He once served as the chairman of the Thyroid Cancer Professional Committee of the Chinese Anti-Cancer Association, and currently serves as the chairman of the Head and Neck Cancer Professional Committee of the Chinese Anti-Cancer Association. He is also the chairman of the Tianjin Thyroid Cancer Professional Committee and other academic positions. The Department of Thyroid and Neck Oncology has not only inherited the superb surgical skills and rigorous work attitude of the older generation of medical workers, but also inherited the nationally renowned medical characteristics of the original Head and Neck Department. It took the lead in formulating the standardized guidelines for thyroid tumors in my country and became the setter of standardized standards for the thyroid tumor treatment industry in my country. The Department of Thyroid and Neck Oncology has strong clinical technology and skilled surgical expertise. It has experienced and highly qualified head and neck oncologists, and has world-leading treatment methods and methods. As the birthplace of head and neck surgery in my country, the purpose of medical work is "inheritance and development". In clinical treatment, it not only inherits the traditional medical characteristics of the original head and neck surgery, but also constantly seeks development and meets new challenges through technological improvement and technological innovation. Nowadays, the Department of Thyroid and Neck Oncology has formed a more representative and distinctive surgical treatment system for the treatment of malignant tumors of the head and neck. For example, the surgical treatment of thyroid cancer places special emphasis on individualized treatment and function-preserving surgical treatment. Taking papillary thyroid cancer as an example, we are the first to propose the concept of thyroid cancer risk stratification in China. We conduct a detailed analysis of each patient's pathological sections based on the WHO's new histological classification of thyroid tumors. We also combine the patient's age, primary tumor size and other factors to develop a treatment plan suitable for the patient, and then perform corresponding surgical treatment. The department also actively carries out functional surgery in clinical practice, that is, functional preservation and functional reconstruction. Among them, function-preserving surgery mainly performs multi-functional cervical lymph node dissection, nerve transplantation, parathyroid dissection, preservation and transplantation, etc. On the premise of not affecting the complete tumor resection, the patient's function is preserved and the appearance is perfect, which improves the patient's quality of life after surgery. In addition, the department has gradually carried out laparoscopic-assisted thyroidectomy and cervical lymph node dissection in recent years, including laparoscopic-assisted axillary approach thyroidectomy + ipsilateral central lymph node dissection, laparoscopic-assisted oral approach thyroidectomy + central lymph node dissection, and robot-assisted thyroidectomy + central lymph node dissection, achieving the goal of "markless neck" cosmetic surgery, improving the postoperative satisfaction of thyroid cancer patients, and achieving good results. In addition, the Department of Thyroid and Neck Oncology has a strong thyroid cancer clinical trial platform and a number of nationally-led multi-center clinical studies. At present, the department has concentrated most of the domestic clinical trials of thyroid cancer targeted drugs and biotherapeutic drugs, and there are many international multi-center clinical studies also led by the Thyroid and Neck Oncology Department. International multi-center clinical studies include: sorafenib (domestic lead), vandetanib (domestic lead), lenvatinib (domestic lead), Domestic drugs include: anlotinib (led domestically), apatinib, surufatinib and other targeted drugs have achieved good results. Comprehensive treatment of malignant tumors has also become one of the features of the Department of Thyroid and Neck Oncology. At present, the importance of comprehensive treatment of malignant tumors is increasingly emphasized internationally. On the basis of traditional chemotherapy methods, we actively integrate with international standards, constantly design new technologies and develop new methods to better serve patients. While actively doing clinical work, the department also conducts a large amount of basic research, which beneficially promotes the development of clinical work. He has undertaken a number of projects at all levels, won multiple awards, and published more than 200 papers in domestic and foreign professional magazines. Received: second prize of China Anti-Cancer Association Science and Technology Award, second prize of Tianjin Science and Technology Progress Award, third prize of China Science and Technology Award and other national and provincial and ministerial level science and technology awards. The chief editor's monographs of the Department of Thyroid and Neck Oncology include: "Thyroid Oncology", "Head and Neck Oncology Third Edition", "100 Questions and Answers on Thyroid Tumors", "Diagnosis, Treatment and Prognosis of Head and Neck Tumors", "Standards for the Diagnosis and Treatment of Head and Neck Tumors" (1992, 2003), the audio-visual textbooks of the Ministry of Health "Combined Radical Surgery for Thyroid Cancer", "Head and Neck Oncology", "New Head and Neck Oncology", "Diagnosis and Treatment Plans for Common Tumors", and "Oral and Maxillofacial Oncology". Staff at all levels in the department have participated in the compilation of more than 20 treatises at all levels inside and outside the hospital, including: "Surgical Judgments", "Modern Oncology Surgery", "Oncology Questions and Answers", "Clinical Oncology", "Concise Oncology", "Standards for Chemotherapy of Malignant Tumors", "21st Century Cross-Century Series - Head and Neck Tumors", "Oncology Surgery", etc. View full introduction

Hepatobiliary Tumor Department›

The Department of Hepatobiliary Oncology of Tianjin Medical University Cancer Hospital was formerly known as the Department of Abdominal Oncology Surgery of Tianjin Medical University Cancer Hospital. It gradually developed and expanded with the efforts of a large number of famous experts such as Wang Dianchang, Hao Xishan, and Li Qiang, and trained and trained a large number of influential experts in abdominal oncology surgery at home and abroad. In 1998, it became an independent department of hepatobiliary oncology. In recent years, relying on the overall multidisciplinary advantages of Tianjin Medical University Cancer Hospital, it has achieved rapid development and has become an internationally advanced and domestically leading position. Approved as a doctorate-granting site in 1999, it is the leading unit of hepatobiliary tumor surgery in Tianjin that integrates medical care, teaching, and scientific research. Department status In addition to the general outpatient clinic, specialist outpatient clinic and special outpatient clinic for hepatobiliary tumors, this department also has a combined hepatobiliary tumor clinic (MDT), including the Department of Hepatobiliary Oncology, Department of Gastrointestinal Oncology, Department of Radiotherapy, Department of Interventional Therapy, Department of Biotherapy, Department of Ultrasound, Department of Radiology, and Department of Pathology. A total of 8 experts visit at the same time to jointly formulate treatment plans for patients. The annual outpatient volume of the department can reach 20,000, among which the joint hepatobiliary tumor clinic completes more than 200 difficult case consultations every year. It currently has 2 floors of general wards and 1 intensive care unit, with a total of 118 beds. It treats more than 3,500 patients every year, and the hospital bed utilization rate reaches 110%. Most of the patients admitted are difficult cases referred from various medical units in the city and North and Northeast China. The number of surgeries throughout the year reached more than 2,000. The department ward has instruments and equipment that are in line with international standards such as color ultrasound Doppler diagnostic instrument, liver reserve function tester, three-dimensional liver reconstruction and liver volume assessment instrument, ultrasonic surgical aspirator (CUSA), STORZ laparoscope, radiofrequency ablation instrument, etc., which has greatly enhanced the sustainable development capabilities of medical technology and has always been at the international advanced and domestic leading level. Medical professional features Surgical treatment of liver cancer: Anatomic liver resection and precision liver resection; Anterior approach liver resection; Very large liver resection; Glisson sheath transverse liver resection; Liver segment staining hepatectomy; Ex vivo liver resection; Bloodless hepatectomy with total hepatic blood flow obstruction; Preoperative portal vein embolization and second-stage liver resection; Re-resection of recurrent liver cancer; Laparoscopic hemihepatectomy and segmental liver resection; Combined liver dissection and portal vein ligation two-step hepatectomy (ALPPS). Radiofrequency ablation treatment of liver tumors: Percutaneous radiofrequency ablation of liver tumors (including artificial chest and radiofrequency ablation of liver tumors under ascites); Laparoscopic radiofrequency ablation of liver tumors; Open radiofrequency ablation of liver tumors; Radical resection of gallbladder cancer according to T stage. Radical resection of hilar cholangiocarcinoma: Radical resection of hilar cholangiocarcinoma combined with hemihepatectomy and caudate lobe resection; Radical revascularization for hilar cholangiocarcinoma. Pancreatoduodenectomy: Various laparoscopic pancreaticoduodenectomies for distal cholangiocarcinoma, pancreatic cancer, and ampullary cancer; duodenum-preserving pancreatic head resection; Pancreatic head-preserving duodenectomy; Hemihepatectomy combined with pancreaticoduodenectomy; Revascularized pancreaticoduodenectomy. Robotic hepatobiliary and pancreatic surgery The department pays attention to the promotion of medical technology and hosts a number of seminars and classes on clinical diagnosis and treatment of hepatobiliary tumors every year, achieving good profits and reputation. The Tianjin Hepatobiliary Surgery Young Physician Salon is held regularly to update new treatment concepts, new methods, and new technologies in a timely manner. The International Summit Forum on Standardized Diagnosis and Treatment of Hepatobiliary Tumors is held every two years, and famous domestic and foreign hepatobiliary surgery experts are invited to attend and give lectures. Concept technology frontier EARS Enhanced recovery after surgery (ERAS): refers to a series of optimization measures for perioperative treatment using evidence-based medical evidence to reduce the physical and psychological traumatic stress of surgical patients and achieve rapid recovery. Professor Song Tianqiang, director of the department, applied the concept of rapid postoperative recovery to the clinical practice of surgery in our hospital and achieved good results. In 2006, he received a scientific research fund project supported by the Tianjin Municipal Health and Family Planning Commission. It has now become a routine diagnosis and treatment measure in the department, shortening hospitalization time, reducing postoperative complications, and reducing patients' financial burden. MDT Multidisciplinary collaborative treatment model (multiple disciplinary team, MDT): refers to a clinical multidisciplinary team, that is, a clinical discussion meeting held by multidisciplinary experts around a certain case, and a treatment plan is formulated for the patient based on the comprehensive opinions of various disciplines. Because of its distinctive patient-centered and individualized treatment characteristics. MDT has become an important mode of disease treatment in large foreign hospitals and tumor treatment centers. In October 2011, Tianjin Medical University Cancer Hospital established a domestic joint outpatient clinic focusing on the treatment of difficult hepatobiliary tumors (hepatobiliary tumor multidisciplinary comprehensive diagnosis and treatment joint outpatient clinic), and has many joint disciplines (hepatobiliary tumor surgery, digestive oncology, internal medicine, Department of Interventional Therapy, Department of Radiation Therapy, Department of Biotherapy, Department of Ultrasound Diagnosis and Treatment, Department of Radiology, Department of Pathology), each year treats about 200 difficult cases of hepatobiliary tumors from all over the country, which has improved the comprehensive diagnosis and treatment level and efficacy of difficult cases of hepatobiliary tumors in our hospital. Radiofrequency ablation treatment of liver tumors based on liver surgery technology support Radiofrequency ablation is an emerging technology in recent years. For some small liver tumors, it can achieve effects close to surgical treatment. This technology is mostly mastered by doctors in the ultrasound department and oncology department. The indications for surgery are not well understood, which blindly expands the indications for radiofrequency ablation treatment. Based on the support of liver surgery technology, our department strictly distinguishes the indications of surgery and radiofrequency ablation, and chooses surgery or radiofrequency ablation based on the patient's individual condition in order to achieve the best results. Radical resection of gallbladder cancer based on TNM staging and T staging of gallbladder cancer Gallbladder cancer is discovered late and has a poor prognosis. It is often discovered accidentally during diagnosis and treatment in general hospitals or during surgery. General hospitals have certain deviations in the radical treatment of gallbladder cancer. Our department implements different surgical treatment plans based on the TNM stage and T stage of gallbladder cancer. Simple cholecystectomy is performed for T1a gallbladder cancer. For T1b gallbladder cancer, combined resection of liver segments IVb and V and hepatoduodenal ligament lymph node dissection are required. Talent training and medical education The Department of Hepatobiliary Oncology has strong technical force, focuses on talent training, and has a reasonable talent echelon composed of old, middle-aged and young people. We have a professional, young, high-level academic team with teamwork spirit. There are currently 66 medical staff, including 1 academician of the Chinese Academy of Engineering, 2 experts enjoying national special subsidies, 1 new century outstanding talent from the Ministry of Education, 3 Tianjin “131 Innovative” talents, 2 professors and doctoral supervisors, 2 master supervisors, 5 chief physicians, 4 deputy chief physicians, 4 attending physicians, and 3 resident physicians. The Department of Hepatobiliary Oncology has always attached great importance to talent training and introduction. All doctors have obtained doctorate degrees, including one doctor in Japan, 10 of whom have returned from studying abroad, and studied in Japan and Australia respectively. Many doctors are studying in internationally renowned hepatobiliary surgery centers. There are 6 nurses with master's degrees. The number, age structure, and academic structure of medical staff are reasonable. The department is responsible for clinical teaching, internship and internship teaching for foreign students in the seven-year program of Tianjin Medical University and the International College, and is responsible for doctoral and master's degree education in hepatobiliary oncology. It recruits doctoral and master's degree students from all over the country, and also recruits foreign master's degree students. Every year, we accept clinical training doctors from all over the country to promote new medical technologies. All doctors in the department can undertake the teaching tasks of basic clinical courses and internship teaching tasks for medical students of the Medical University. At the same time, some teachers also undertake the English teaching of the International School of Clinical Medicine. The characteristics of postgraduate training in this discipline are the close integration of theory and practice, and equal emphasis on scientific research and clinical skills, making them comprehensive talents with strong clinical work ability, teaching ability and scientific research ability. Academic exchange The department pays attention to mutual exchanges and learning at home and abroad, and has sent doctors to visit and study at home and abroad many times. It has also maintained good long-term academic exchanges and cooperation with the University of Tokyo Hospital in Japan, Towa Hospital in Japan, Bundang Hospital of the National University of Korea, Kaohsiung Chang Gung Memorial Hospital in Taiwan, National Taiwan University Hospital, Yadong Memorial Hospital in Taiwan, and Changbin Hideden Hospital in Taiwan. Relevant experts have been invited to give lectures and exchanges many times. Many doctors have long-term study and training experience abroad, which has established a stable international communication channel for the department. Many experts from the department have given special academic reports at international academic conferences and won high praise from foreign colleagues. The overseas further study of subject leaders and young and middle-aged backbones has broadened the professional perspective of doctors, enhanced the innovative ability of young doctors, and improved the concept of international medical services. scientific research In the past five years, the Department of Hepatobiliary Oncology has undertaken 6 national key projects (major special projects, science and technology support plans, 973 projects), 3 National Clinical Medicine Center projects, 4 National Natural Science Foundation projects, and 7 provincial and municipal projects. Doctors in the department have published more than 100 high-quality SCI papers and Chinese domestic core journal papers. It has led and participated in more than 20 international and domestic multi-center clinical trials related to hepatobiliary tumors, actively improved diagnosis and treatment evidence, continued to improve diagnosis and treatment standards, continuously promoted the hospital's international reputation, and provided patients with valuable free treatment opportunities. View full introduction

Hepatobiliary Medical Oncology Department›

Department of Hepatobiliary Oncology, Tianjin Medical University Cancer Hospital 1. Department history The Department of Hepatobiliary Oncology of Tianjin Medical University Cancer Hospital was formerly known as the Department of Abdominal Oncology Surgery of Tianjin Medical University Cancer Hospital. It gradually developed and expanded with the efforts of a large number of famous experts such as Wang Dianchang, Hao Xishan, and Li Qiang, and trained and trained a large number of influential experts in abdominal oncology surgery at home and abroad. In 1998, it became an independent department of hepatobiliary oncology. In recent years, relying on the overall multidisciplinary advantages of Tianjin Medical University Cancer Hospital, it has achieved rapid development and has become an internationally advanced and domestically leading position. Approved as a doctorate-granting site in 1999, it is the leading unit of hepatobiliary tumor surgery in Tianjin that integrates medical care, teaching, and scientific research. 2. Current situation of the department In addition to the general outpatient clinic, specialist outpatient clinic and special outpatient clinic for hepatobiliary tumors, this department also has a combined hepatobiliary tumor clinic (MDT), including the Department of Hepatobiliary Oncology, Department of Gastrointestinal Oncology, Department of Radiotherapy, Department of Interventional Therapy, Department of Biotherapy, Department of Ultrasound, Department of Radiology, and Department of Pathology. A total of 8 experts visit at the same time to jointly formulate treatment plans for patients. The annual outpatient volume of the department can reach 20,000, among which the joint hepatobiliary tumor clinic completes more than 200 difficult case consultations every year. Our department currently has 2 floors of general wards and 1 intensive care unit, with a total of 118 beds. It treats more than 3,500 patients every year, and the hospital bed utilization rate reaches 110%. Most of the patients admitted are difficult cases referred from various medical units in the city and North and Northeast China. The number of surgeries throughout the year reached more than 2,000. The department ward has instruments and equipment that are in line with international standards such as color ultrasound Doppler diagnostic instrument, liver reserve function tester, three-dimensional liver reconstruction and liver volume assessment instrument, ultrasonic surgical aspirator (CUSA), STORZ laparoscope, radiofrequency ablation instrument, etc., which greatly enhances the sustainable development capability of our department's medical technology and has always been at the internationally advanced and domestic leading level. 3. Features of medical profession Surgical treatment of liver cancer: Anatomic liver resection and precision liver resection; Anterior approach liver resection; Very large liver resection; Glisson sheath transverse liver resection; Liver segment staining hepatectomy; Ex vivo liver resection; Bloodless hepatectomy with total hepatic blood flow obstruction; Preoperative portal vein embolization and second-stage liver resection; Re-resection of recurrent liver cancer; Laparoscopic hemihepatectomy and segmental liver resection; Combined liver dissection and portal vein ligation two-step hepatectomy (ALPPS). Radiofrequency ablation treatment of liver tumors: Percutaneous radiofrequency ablation of liver tumors (including artificial chest and sub-ascites radiofrequency ablation of liver tumors) Laparoscopic radiofrequency ablation of liver tumors Open radiofrequency ablation of liver tumors Radical resection of gallbladder cancer according to T stage Radical resection of hilar cholangiocarcinoma: Radical resection of hilar cholangiocarcinoma combined with hemihepatectomy and caudate lobe resection; Radical revascularization for hilar cholangiocarcinoma. Pancreatoduodenectomy: Various laparoscopic pancreaticoduodenectomies for distal cholangiocarcinoma, pancreatic cancer, and ampullary cancer; duodenum-preserving pancreatic head resection; Pancreatic head-preserving duodenectomy; Hemihepatectomy combined with pancreaticoduodenectomy; Revascularized pancreaticoduodenectomy; Robotic hepatobiliary and pancreatic surgery: The department pays attention to the promotion of medical technology and hosts a number of seminars and classes on clinical diagnosis and treatment of hepatobiliary tumors every year, achieving good profits and reputation. The Tianjin Hepatobiliary Surgery Young Physician Salon is held regularly to update new treatment concepts, new methods, and new technologies in a timely manner. The International Summit Forum on Standardized Diagnosis and Treatment of Hepatobiliary Tumors is held every two years, and famous domestic and foreign hepatobiliary surgery experts are invited to attend and give lectures. 4. Concept and technology frontier EARS Enhanced recovery after surgery (ERAS): refers to a series of optimization measures for perioperative management with evidence-based medical evidence to reduce the physical and psychological traumatic stress of surgical patients and achieve rapid recovery. Professor Song Tianqiang, director of the department, applied the concept of rapid postoperative recovery to the clinical practice of surgery in our hospital and achieved good results. In 2006, he received a scientific research fund project supported by the Tianjin Municipal Health and Family Planning Commission. It has now become a routine diagnosis and treatment measure in the department, shortening hospitalization time, reducing postoperative complications, and reducing patients' financial burden. MDT Multidisciplinary collaborative treatment model (multiple disciplinary team, MDT): refers to a clinical multidisciplinary team, that is, a clinical discussion meeting held by multidisciplinary experts around a certain case, and a treatment plan is formulated for the patient based on the comprehensive opinions of various disciplines. Because of its distinctive patient-centered and individualized treatment characteristics. MDT has become an important mode of disease treatment in large foreign hospitals and tumor treatment centers. In October 2011, Tianjin Medical University Cancer Hospital established a domestic joint outpatient clinic focusing on the treatment of difficult hepatobiliary tumors (hepatobiliary tumor multidisciplinary comprehensive diagnosis and treatment joint outpatient clinic), and has many joint disciplines (hepatobiliary tumor surgery, digestive oncology, internal medicine, Department of Interventional Therapy, Department of Radiation Therapy, Department of Biotherapy, Department of Ultrasound Diagnosis and Treatment, Department of Radiology, Department of Pathology), each year treats about 200 difficult cases of hepatobiliary tumors from all over the country, which has improved the comprehensive diagnosis and treatment level and efficacy of difficult cases of hepatobiliary tumors in our hospital. Radiofrequency ablation treatment of liver tumors based on liver surgery technology support Radiofrequency ablation is an emerging technology in recent years. For some small liver tumors, it can achieve effects close to surgical treatment. This technology is mostly mastered by doctors in the ultrasound department and oncology department. The indications for surgery are not well understood, which blindly expands the indications for radiofrequency ablation treatment. Based on the support of liver surgery technology, our department strictly distinguishes the indications of surgery and radiofrequency ablation, and chooses surgery or radiofrequency ablation based on the patient's individual condition in order to achieve the best results. Radical resection of gallbladder cancer based on TNM staging and T staging of gallbladder cancer Gallbladder cancer is discovered late and has a poor prognosis. It is often discovered accidentally during diagnosis and treatment in general hospitals or during surgery. General hospitals have certain deviations in the radical treatment of gallbladder cancer. Our department implements different surgical treatment plans based on the TNM stage and T stage of gallbladder cancer. Simple cholecystectomy is performed for T1a gallbladder cancer. For T1b gallbladder cancer, combined resection of liver segments IVb and V and hepatoduodenal ligament lymph node dissection are required. 5.Talent training and medical education The Department of Hepatobiliary Oncology has strong technical force, focuses on talent training, and has a reasonable talent echelon composed of old, middle-aged and young people. We have a professional, young, high-level academic team with teamwork spirit. There are currently 66 medical staff, including 1 academician of the Chinese Academy of Engineering, 2 experts enjoying national special subsidies, 1 new century outstanding talent from the Ministry of Education, 3 Tianjin “131 Innovative” talents, 2 professors and doctoral supervisors, 2 master supervisors, 5 chief physicians, 4 deputy chief physicians, 4 attending physicians, and 3 resident physicians. Our department has always attached great importance to talent training and introduction. All doctors have obtained doctorate degrees, including 1 doctor in Japan, 10 of whom have returned from studying abroad, and studied in Japan and Australia respectively. Many doctors are studying in internationally renowned hepatobiliary surgery centers. There are 6 nurses with master's degrees. The number, age structure, and academic structure of medical staff are reasonable. The department is responsible for clinical teaching, internship and internship teaching for foreign students in the seven-year program of Tianjin Medical University and the International College, and is responsible for doctoral and master's degree education in hepatobiliary oncology. It recruits doctoral and master's degree students from all over the country, and also recruits foreign master's degree students. Every year, we accept clinical training doctors from all over the country to promote new medical technologies. All doctors in the department can undertake the teaching tasks of basic clinical courses and internship teaching tasks for medical students of the Medical University. At the same time, some teachers also undertake the English teaching of the International School of Clinical Medicine. The characteristics of postgraduate training in this discipline are the close integration of theory and practice, and equal emphasis on scientific research and clinical skills, making them comprehensive talents with strong clinical work ability, teaching ability and scientific research ability. 6.Academic exchange The department pays attention to mutual exchanges and learning at home and abroad, and has sent doctors to visit and study at home and abroad many times. It has also maintained good long-term academic exchanges and cooperation with the University of Tokyo Hospital in Japan, Towa Hospital in Japan, Bundang Hospital of the National University of Korea, Kaohsiung Chang Gung Memorial Hospital in Taiwan, National Taiwan University Hospital, Yadong Memorial Hospital in Taiwan, and Changbin Hideden Hospital in Taiwan. Relevant experts have been invited to give lectures and exchanges many times. Many doctors have long-term study and training experience abroad, which has established a stable international communication channel for the department. Many experts from the department have given special academic reports at international academic conferences and won high praise from foreign colleagues. The overseas further study of subject leaders and young and middle-aged backbones has broadened the professional perspective of doctors, enhanced the innovative ability of young doctors, and improved the concept of international medical services. 7. Scientific research In the past five years, the Department of Hepatobiliary Oncology has undertaken 6 national key projects (major special projects, science and technology support plans, 973 projects), 3 National Clinical Medicine Center projects, 4 National Natural Science Foundation projects, and 7 provincial and municipal projects. Doctors in the department have published more than 100 high-quality SCI papers and Chinese domestic core journal papers. It has led and participated in more than 20 international and domestic multi-center clinical trials related to hepatobiliary tumors, actively improved diagnosis and treatment evidence, continued to improve diagnosis and treatment standards, continuously promoted the hospital's international reputation, and provided patients with valuable free treatment opportunities. View full introduction

Gynecologic Oncology Department Department›

The Department of Gynecological Oncology of Tianjin Medical University Cancer Hospital was formerly known as the Department of Pelvic Oncology of Tianjin Cancer Hospital. It was founded in 1952 and was the first department in Tianjin to carry out radical surgeries for various pelvic malignant tumors. It is a professional department that focuses on surgery and comprehensively uses chemotherapy, radiotherapy, interventional therapy and targeted therapy to diagnose and treat various malignant gynecological tumors such as ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer, vaginal cancer, peritoneal cancer and various benign gynecological tumors. It has a professional team with good medical ethics, rich experience, superb skills, advanced equipment and high-quality care. Currently, there are 20 doctors in the Department of Gynecological Oncology, 95% of whom are doctors and masters, including 5 chief physicians, 5 deputy chief physicians, and 94 beds. In 2016, it performed more than 1,600 surgeries and is an important and prestigious gynecological oncology diagnosis and treatment department in northern my country. After several generations of unremitting efforts, we have extensively absorbed advanced experience at home and abroad, emphasizing the standardized treatment of gynecological malignant tumors and forming its own distinctive characteristics in individual and comprehensive treatment. We are especially good at surgery, chemotherapy and comprehensive treatment of refractory and recurrent gynecological malignant tumors. As a department with traditional surgical advantages, it has rich experience in complex ovarian cancer cytoreduction, comprehensive staging of ovarian cancer, nerve-sparing radical hysterectomy, wide resection of vulvar cancer, retroperitoneal lymph node dissection, pelvic organ dissection and other difficult surgeries for gynecological tumors. Be the first to carry out fertility-preserving surgery for early-stage cervical cancer in Tianjin. The application of modern technologies such as laparoscopy, hysteroscopy, and "Da Vinci" robots allows patients to experience less postoperative trauma and faster recovery. Members of the department have rich clinical experience in chemotherapy for gynecological malignant tumors, especially the selection and rational application of second-line, third-line drugs and targeted drugs for ovarian cancer, and have achieved remarkable clinical results. Relying on the strong clinical research advantages of Tianjin Medical University Cancer Hospital, we carry out multi-specialty collaborative treatment (MDT) of gynecological malignant tumors and work closely with relevant departments to provide patients with phase I and follow-up clinical trials, PET-CT examinations, HPV gene testing, circulating tumor cell detection, tumor genetic counseling, uterine Advanced treatment options such as arterial interventional chemotherapy, bone metastasis isotope therapy, tumor seed implantation, short-range three-dimensional intracavitary radiotherapy, external conformal intensity-modulated radiotherapy, cyberknife, and traditional Chinese medicine strengthening and conditioning have maximized the survival time of patients and improved their quality of life, and have won widespread praise from colleagues and patients at home and abroad. The Department of Gynecological Oncology focuses on basic and clinical research on gynecological tumors, pays close attention to domestic and foreign subject trends and new developments, and actively carries out external exchanges and cooperation. In recent years, he has published more than 10 papers in national core journals and SCI magazines every year. He has undertaken a number of research projects from the National Natural Science Foundation, Tianjin Science and Technology Commission, Education Commission, Health Bureau, Tianjin Medical University, etc., and has achieved fruitful research results. He has reached cooperative relationships with a number of research institutions and has participated in a number of clinical studies. He has participated in the preparation of monographs such as "Abdominal Oncology", "Tumor Surgery" and "Concise Oncology", and has published research reports at domestic and foreign academic conferences many times. The department undertakes various teaching tasks for undergraduates, graduate students and international students of Tianjin Medical University. At present, it has a team that integrates medical care, teaching and scientific research, with a reasonable structure and a complete echelon. In 2014, Tianjin Medical University Cancer Hospital was selected as the National Cancer Clinical Center, and subsequently was selected as the National Health and Family Planning Commission’s Diagnosis and Treatment Center for Difficult and Severe Diseases, which provides unprecedented opportunities for the development of gynecological oncology. We will continue to forge ahead and provide advanced and high-quality technologies and services to the majority of gynecological cancer patients, helping patients to stay away from cancer and regain a new life. View full introduction

Pulmonary Tumor Department›

The Department of Pulmonary Oncology of Tianjin Medical University Cancer Hospital is one of the earliest teams in China to carry out multidisciplinary comprehensive treatment of a single type of lung cancer. In 1998, the department was established as the third department of internal oncology and renamed the Department of Pulmonary Oncology in 2006. It is a clinical department characterized by lung tumor diagnosis, differential diagnosis, chemotherapy, molecular targeted therapy, immunotherapy, clinical research on new anti-cancer drugs and multidisciplinary comprehensive treatment. Tailor-made individualized treatment plans are provided for patients. Lung cancer diagnosis and medical treatment are at the domestic first-class level, and the diagnosis and treatment model is in line with international standards. The Department of Pulmonary Medicine has a total of 74 beds and 35 medical staff, including 15 physicians, 1 clinical researcher, 5 technicians with senior professional titles, and 3 technicians with deputy senior professional titles. The department has successively undertaken National Natural Science Foundation projects, Tianjin Municipal Education Commission and Science and Technology Commission, bureau-level, and school-level scientific research projects. It has published hundreds of papers in domestic and foreign journals, including more than 100 SCI-included papers. As a national-level clinical research base for new anti-cancer drugs, the Department of Pulmonary Medicine has followed new international development trends over the years and has hosted or participated in dozens of new drug clinical trials of anti-cancer drugs. The number and quality of enrollment ranks among the top in the country. It is currently conducting multiple international and domestic clinical studies of new drugs and related topics. The department led a phase III study (ALTER0303) to evaluate the efficacy and safety of anlotinib as a third-line treatment for advanced NSCLC. The results of the study have received widespread international recognition and attention, injecting fresh power into anti-angiogenic therapy and bringing new breakthroughs to the third-line treatment of advanced non-small cell lung cancer. It not only benefits patients, but also provides new treatment options for clinicians. Currently, a Phase III clinical trial of BGB-A317 (anti-PD-1 antibody) versus docetaxel for the second-line and above treatment of advanced NSCLC and a Phase II clinical trial of anlotinib as a third-line and above treatment for small cell lung cancer are currently being carried out. In the future, we will further evaluate anlotinib as a second-line treatment for advanced NSCLC, anlotinib combined with icotinib as a first-line treatment for EGFR mutated advanced NSCLC, and a series of translational and clinical studies on small cell lung cancer, and clinical studies on immunotherapy. As a training center for doctoral and master's students of Tianjin Medical University, the department has 2 doctoral supervisors and 3 master's supervisors. It is responsible for teaching doctoral and master's degree students, undertaking academic exchanges and continuing education tasks for medical oncology across the country, attracting many oncology specialists and clinical pharmacists from all over the country to come for further studies, and training several oncology professionals for oncology specialties across the country every year. The Department of Pulmonary Medicine has a specialist oncology nursing team with extensive experience in the prevention and treatment of chemical injuries to vascular access. Carry out the construction of vomiting-free wards to actively prevent and treat chemotherapy-related nausea and vomiting. Carry out regular patient care and education to help patients have a correct understanding of chemotherapy, eliminate patients' fear, alleviate patients' psychological and physical pain in an all-round way, and strive to improve patients' quality of life. All medical staff in the Department of Lung Oncology will do their best to provide high-quality services to the majority of cancer patients with superb technology, good medical ethics and a high sense of responsibility based on the patient-centered service concept. View full introduction

Radiotherapy›

The Radiotherapy Department of Tianjin Medical University Cancer Hospital is a cancer treatment center with a long history and heritage. The department was founded in 1970 (radiation therapy group), with 30 approved beds and 5 doctors. In 1978, the Department of Radiotherapy was established with 50 approved beds. Jin Xianzhai was the director and there were 8 doctors. By the end of 1987, the number of approved beds increased to 90, and the number of doctors increased to 24. In order to carry out in-depth radiotherapy for tumors in different parts of the department, the department is divided into four groups: head and neck, chest, abdomen, and breast, each focusing on their work. In November 1999, the department established two secondary departments, namely: Radiation Physics Room and Maintenance Room. There are 84 staff members in total. In 2013, the Radiobiology Laboratory was established. In 2008, based on the original professional groupings, three professional groups were established: head and neck tumors and lymphoma, chest tumors, and abdominal and pelvic tumors. Doctors strictly admit and treat patients according to disease types. As of October 2011, there were 146 approved beds and more than 100 staff members. As of April 2018, the Department of Radiotherapy has established the first radiotherapy ward, the second radiotherapy ward, the comprehensive radiotherapy ward, the radiotherapy center, and the Cyber ​​Knife Center, with more than 160 medical staff. These include doctors, technicians, physicists, engineers, nurses and other professionals. The radium tubes and radium needles brought back from abroad by Professor Jin Xianzhai, the father of Chinese oncology, were first used in hospitals for the treatment of cervical cancer patients and head and neck tumor patients. In 1979, under the personal care of Professor Jin Xianzhai, a hyperthermia research group was established. The group undertook and completed the national "Eighth Five-Year Plan" research project. In order to cooperate with tumor temperature measurement, Lin Shiyin, Li Ruiying and others successfully developed non-interference temperature measurement technology and instruments for tumor hyperthermia, and won the second prize of the National Invention Award. Since 1990, radical radiotherapy for early-stage breast cancer after breast-conserving surgery has been carried out. This technology is becoming more and more perfect and has now become a routine treatment after breast-conserving surgery for breast cancer, and won the second prize of the Medical University's Scientific and Technological Progress Award. Using the Iridium 192 post-loading machine, we have carried out intraluminal treatment and inter-tissue implantation treatment of tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, floor of the mouth cancer, tongue cancer, breast cancer, etc. We have cooperated with the Department of Surgery to carry out intraoperative inter-tissue treatment of limb tumors, brain tumors, and retroperitoneal tumors, and achieved good results. Since the end of 2006, the Department of Radiotherapy has introduced the CMS intensity-modulated radiotherapy planning system. Under the auspices of President Wang Ping, it has successfully carried out conformal intensity-modulated radiotherapy, which has improved the efficacy of radiotherapy for patients with intermediate and advanced stages and minimized the risk of radiation complications. So far, it has completed intensity-modulated radiotherapy for head and neck tumors, chest tumors, and abdominal and pelvic tumors, and achieved good therapeutic effects. At the end of the same year, a CyberKnife stereotactic radiosurgery treatment equipment was purchased, and stereotactic radiosurgery was carried out for intracranial tumors, spinal canal tumors, body tumors, etc., and achieved good results. At present, the Department of Radiotherapy can carry out conventional radiotherapy, conformal radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, post-loading and inter-tissue brachytherapy, hyperthermia and other radiotherapy techniques for tumors in various parts of the body. It has a technical team with precise positioning, precise planning and precise treatment, and has become one of the well-known radiotherapy centers in the country. At present, under the leadership of the subject leader Professor Wang Ping, the Department of Radiation Therapy has made great achievements in clinical, scientific research and teaching aspects. It currently has 3 doctoral supervisors and 4 master supervisors. During the 12th Five-Year Plan period, we actively carried out research on the application of CyberKnife, an image-guided stereotactic radiotherapy robot technology, introduced high-precision radiotherapy technologies such as volumetric intensity-modulated radiotherapy and image-guided radiotherapy, and cooperated with domestic and foreign R&D personnel to develop new image-guided radiotherapy technologies. We successfully applied various advanced radiotherapy technologies to the treatment of malignant tumors such as lung cancer, esophageal cancer, cervical cancer, and nasopharyngeal cancer, and achieved good clinical treatment results. A radiation biology laboratory has been established to conduct in-depth research on molecular biology issues in the process of tumor radiation therapy, and to explore various aspects to better enhance the efficacy of radiation therapy in treating malignant tumors. The CyberKnife team led by Professor Yuan Zhiyong has successfully applied advanced hypofractionated stereotactic radiotherapy technology to the treatment of early-stage lung cancer, liver cancer, pancreatic cancer, vertebral body metastasis cancer, brain tumors, etc., and has conducted systematic research on the radiobiological basis of hypofractionated radiotherapy, and also conducted extensive research on issues related to radiation physics during the application of CyberKnife. Professor Zhao Lujun led the team to actively carry out research on individualized radiotherapy for lung cancer, and conducted a large number of studies on postoperative radiotherapy for non-small cell lung cancer, combined application of radiotherapy and chemotherapy for small cell lung cancer, radiation-induced lung injury, combined application of radiotherapy and immunotherapy, and the role of transforming growth factor in tumor radiotherapy. Chief Physician Zhu Zhu, Deputy Chief Physician Wang Peiguo, and Chief Physician Pang Qingsong have also conducted a number of clinical and basic research on cervical cancer, nasopharyngeal cancer, and esophageal cancer respectively, improving the efficacy of tumor treatment. During this period, the radiotherapy team led by Dean Wang Ping obtained 15 national projects and 6 provincial and ministerial projects during the 12th Five-Year Plan period, published more than 60 SCI papers, with a total impact factor of 140 points, trained more than 30 master's students (more than 10 graduated), 7 doctoral students (1 graduated), and 6 people went abroad for further study. Dean Wang Ping was rated as a young and middle-aged expert with outstanding contributions by the Ministry of Health in 2014, and received a special allowance from the State Council. The Department of Radiotherapy is one of the advantageous departments of our hospital. It handles more than 500 radiotherapy patients every day, ranking at the forefront of major cancer centers across the country, and its influence across the country is also growing. Professor Wang Ping, the subject leader, is currently the chairman of the Special Committee on Radiotherapy oncology of the Chinese Anti-Cancer Association and a standing member of the Radiation Oncology Branch Committee of the Chinese Medical Association. Director Yuan Zhiyong and Deputy Director Zhao Lujun of the Department of Radiotherapy are both standing members of the Special Committee on Radiotherapy oncology of the Chinese Anti-Cancer Association. There are also many members or standing committee members in other national academic organizations on radiotherapy oncology, which indicates that the radiotherapy discipline has a high academic status in the country. Radiotherapy Physics Room The department was founded in 1987 and is a secondary department of the Department of Radiotherapy. It is mainly responsible for the design of various treatment radiation plans for patients, quality assurance and control of accelerators, CT simulation and simulation positioning, hyperthermia, lead mold making and brachytherapy. Intracavitary intubation treatment includes: nasopharyngeal cancer, esophageal cancer, lung cancer, cervical cancer, and rectal cancer. Intertissue implantation includes tongue cancer, gum cancer, limb tumors, perineal tumors, intracranial tumors, and pancreatic cancer. Wang Ping took the lead in carrying out the technically complex and difficult bronchial transplantation technology for lung cancer and the transplantation treatment for tongue cancer and gum cancer, and achieved good results. He also cooperated with the limb department to carry out inter-tissue transplantation after limb tumor surgery, and cooperated with the brain surgery department of Tianjin Huanhu Hospital to develop a new technology for intracranial tumor intubation and post-loading radiotherapy. From 1990 to 2000, the annual workload of aftertreatment therapy was more than 720 patients. The external radiation treatment plan mainly treats radical radiotherapy after breast-conserving surgery for early-stage breast cancer, and has accumulated more than 130 cases. In 1990, Wang Ping and Li Ruiying took the lead in developing this technology in China. In 1999, they conducted the Tianjin Science and Technology Achievements Appraisal and won the second prize for the Science and Technology Achievements of Tianjin Medical University. In 1992, the whole-body irradiation technology for bone marrow transplant patients was launched. Director Yang Xinggang led the technical backbone of the physics room to conduct a large amount of research and dose measurement work, which enabled the technology to be applied in clinical practice, and a total of 153 patients were treated. In 2000, a new fully digital medical linear accelerator, a simulation positioning machine and two planning systems (RenderPlan 3.5 and Leibinger's STP 4.0 system) from Elekta Company of Sweden were introduced. These two planning systems can respectively complete the design of three-dimensional stereotactic radiotherapy plans for the head and body. In the process of X-knife being put into clinical application, all the staff in the physics room overcame difficulties and quickly applied the technology to clinical applications. From September 2000 to September 2011, a total of more than 1,500 cases were completed. In 2006, Tianjin took the lead in launching a new technology of intensity-modulated radiotherapy. A large amount of clinical experience has been accumulated so far. The staff of the radiotherapy physics room preside over and participate in a number of domestic and foreign key research projects, and have published dozens of papers in domestic and foreign professional journals. Radiotherapy Department Maintenance Room The department was founded in 1998 (based on the original maintenance team) and is a secondary department of the Radiotherapy Department. There are 5 engineers, all of whom have been engaged in radiotherapy maintenance work for many years and have strong working abilities. Mainly responsible for the management and maintenance of department equipment. radiobiology room The Radiation Biology Laboratory was established in 2013 as a secondary department of the Department of Radiotherapy. It is mainly responsible for scientific research in the fields of biology, basic medicine, and translational medicine related to radiotherapy. Currently, the Radiation Biology Laboratory has one deputy chief physician, two assistant researchers, and two postdoctoral fellows, all of whom are high-level scientific researchers with doctorate degrees. In the past few years, the Radiation Biology Laboratory has undertaken several scientific research funds at all levels, including 5 National Natural Science Foundation projects, 3 Tianjin Natural Science Foundation projects, 1 Jiangsu Province provincial project, 2 Tianjin Medical University Fund projects, and 1 Tianjin Medical University Cancer Hospital Fund project. It has also obtained rich scientific research results and published dozens of papers in domestic and foreign professional academic journals. Among them, there are more than 20 SCI papers, and he has won 1 third prize and 2 second prizes of Shandong Province Science and Technology Progress Award. View full introduction

Breast Oncology Department 3›

The Third Department of Breast Oncology of Tianjin Medical University Cancer Hospital was officially established in 1972. It was the first to carry out extended radical mastectomy for breast cancer nationwide. With the development of early diagnosis of breast cancer, it also performed modified radical mastectomy for breast cancer with preservation of pectoral muscles, laying the foundation for the nationwide implementation of this surgery. With an in-depth understanding of the biological characteristics of breast cancer, we took the lead in carrying out research on comprehensive treatment of breast cancer in China and achieved significant results in clinical breast cancer treatment, thus establishing our hospital's leading position in breast cancer research in the country. At the same time, nurses in the department began to conduct research on functional recovery exercises for the affected upper limb after breast cancer surgery. After decades of development, it further expanded and established the Asian Breast Cancer Prevention and Treatment Center at the end of 2003. The first, second and third breast departments have a total of 133 beds, with an annual outpatient volume of 25,000 and an annual treatment of 2,000 cases of breast cancer. While strengthening its own development, the Department of Breast Surgery keeps pace with international progress and integrates early diagnosis of primary breast cancer, clinical treatment, pathological diagnosis and basic research, becoming a leading and leading unit with absolute advantages in the field of breast cancer research nationwide. 1. The Breast Center has strong capabilities and rich experience in diagnosis and treatment. The Third Department of Breast Oncology was formally established in 2003, with Professor Zhang Jin as the director. Since its establishment, it has standardized the treatment of breast cancer with reference to international standards. The five-year survival rates of clinical stage I and II breast cancer are 94% and 83% respectively, and the ten-year survival rates are 87% and 67% respectively, both of which are among the leading domestic levels and in sync with the international level in the same period. There are 46 beds in total, and the expert team consists of 2 chief physicians and 3 deputy chief physicians. They have rich clinical experience and are particularly unique in the diagnosis and treatment of breast cancer. They not only treat the patient's disease, but also provide comprehensive attention and guidance to the patient's recovery. 2. New technologies and treatments for breast cancer diagnosis and treatment Actively carry out standardized diagnosis and treatment of breast cancer, with new technology support provided by the central laboratory and breast pathology department. The main task is to carry out standardized and individualized treatment of primary breast cancer cases in accordance with the principles of evidence-based medicine, new results in breast cancer research worldwide, and patient needs. 1. Application of new technology in sentinel lymph node biopsy Currently, lymph node metastasis is an absolute indication for systemic therapy. In the past, determining whether cancer metastasized to regional lymph nodes mainly relied on axillary lymph node dissection, which may cause upper limb dysfunction. Although it is effective for local treatment, axillary lymph node dissection is an unnecessary over-treatment for breast cancer patients whose lymph nodes have not metastasized. The application of new minimally invasive lymph node biopsy technology can determine whether cancer metastasis exists in axillary lymph nodes at a small cost, providing an important basis for determining subsequent treatment plans, and can avoid the pain of extended surgery and chemotherapy for patients without lymph node metastasis. Preliminary research on this technology has been completed and the new technology is ready to enter clinical application. 2. Apply molecular pathology examination results to provide technical support for clinical individualized treatment. In addition to conventional examination methods to determine the risk of breast cancer, molecular-level indicators have begun to be used to assess risk, and protein-level indicators can guide clinical treatment. One of the tasks of the Breast Pathology Department is to provide molecular pathology examination results in addition to traditional examination methods, which can predict the efficacy of different programs and the prognosis of patients, and provide technical support for individualized treatment of patients. 3. Neoadjuvant chemotherapy for breast cancer Locally advanced and recurrent metastatic breast cancer requires effective systemic comprehensive treatment, namely chemoradiotherapy, endocrine therapy and molecular targeted therapy. Due to the diversity of breast cancer treatments and the uncertainty of individual breast cancer responses to treatment, neoadjuvant systemic therapy is currently a reliable method to ensure the effectiveness of systemic therapy. The neoadjuvant treatment for breast cancer adopted by our department has become a routine treatment method and is currently in a leading position in the country. Among the hundreds of cases of neoadjuvant chemotherapy that have been completed, the overall pathological complete response (all tumors disappear) reaches 30%. 4. The effect of breast-conserving surgery for breast cancer has reached international standards Large-scale clinical studies have confirmed the safety of breast-conserving therapy. Preserving the breast while ensuring the therapeutic effect can significantly improve the quality of life of breast cancer patients. With the support of pathological diagnosis and radiotherapy technology, breast-conserving surgical treatment of breast cancer has been widely carried out. The breast-conserving rate is currently leading in the country, and the local recurrence rate is significantly lower than the international average. For breast cancer cases that are not suitable for breast preservation due to large tumors, through effective neoadjuvant treatment, the goal of breast preservation is achieved after shrinking the tumor. 3. Pay attention to the application and promotion of new technologies and treatments to improve the overall treatment level of breast cancer in my country Since its establishment, while completing medical tasks, it has also focused on scientific research and teaching. It has undertaken and participated in many international and national multi-center clinical trials, many international, domestic and provincial and ministerial scientific research projects, won many provincial and ministerial scientific research achievement awards, and published papers in foreign journals. He has published dozens of articles and academic papers in national magazines. He has participated in the compilation and compilation of many monographs and translations. He has accepted more than 100 students from national oncology training courses to provide comprehensive training in surgery, teaching, scientific research, etc., so that he can become a qualified oncology surgeon. View full introduction

Breast Oncology Department›

The First Department of Breast Oncology of Tianjin Medical University Cancer Hospital was established in 1971. With the needs of division of clinical work and the deepening of medical reform, three departments of breast tumors were established on the original basis. The First Department of Breast Oncology was established in 1998. The department is headed by Cao Xuchen. It currently has 10 professional and technical staff, including 2 chief physicians and 4 deputy chief physicians. 4 people hold doctorate and master's degrees. There are 41 beds. From the establishment of the department to 2003, the annual average number of outpatient visits was 2,300, the number of inpatients was 720, and the number of surgeries was 720. The department has strong clinical technical strength, is well-known in the country for its proficiency in surgical expertise, and has a domestic breast tumor team. Every year, a large number of breast tumor patients from all over the country come here, and various difficult surgical cases are completed every year, such as elderly breast cancer, advanced breast cancer, rare breast tumors, metastatic breast cancer, etc. The department can complete nearly a thousand radical breast cancer surgeries every year. It also promotes a large number of breast-conserving surgeries and pioneers the nation's leading breast reconstruction and plastic surgery technologies. Including breast reconstruction after breast cancer surgery, nipple and areola reconstruction, breast reduction surgery, etc., the development of breast-conserving surgery is in line with international breast cancer surgery plans. The department has independently completed or cooperated with other departments and units to undertake 7 national, municipal, school-level and college-level projects, and won 3 municipal-level and bureau-level achievement awards. Plastic surgery after radical mastectomy for breast cancer, including stage I and stage II, was completed in 43 cases. Coarse needle biopsy technology reduces the pain of freezing during surgery and provides a basis for neoadjuvant chemotherapy. The department has published 25 articles in core journals, participated in the preparation of 4 books, and edited "Breast Diseases and Clinical Basis". Since it became a master's program in 1984, it has enrolled 14 7-year master's students from Tianjin Medical University and Nankai University School of Medicine, including 7 graduates and 7 current students. Every year, we regularly recruit students from breast oncologist training courses organized by the Ministry of Health across the country to train senior breast oncologists for the country. In 2003, with the approval of the Ministry of Health, a national continuing education class on “Breast Cancer Progress” was held. View full introduction

Colorectal Tumor Department›

The Colorectal Oncology Department of Tianjin Medical University Cancer Hospital was formerly the Department of Abdominal Oncology established in 1972 by Professor Jin Xianzhai, a famous Chinese oncology expert. Due to the development of the discipline, it was established as an independent department in 2004. Professor Liu Jianzhong and Professor Kong Dalu served as department directors. The department currently has 73 approved beds. It focuses on surgical treatment and features standardized and comprehensive treatment of various types of colorectal tumors. It mainly treats patients with various abdominal and pelvic tumors such as colon tumors, rectal tumors, gastrointestinal stromal tumors, liver metastases from colorectal tumors, and retroperitoneal tumors. The department currently has 19 physicians, including 5 chief physicians, 5 deputy chief physicians, 8 attending physicians, 1 resident physician, and 1 assistant researcher. The chief physician and deputy chief physician all have experience studying abroad in large international cancer centers, and all young and middle-aged physicians have a doctorate in medicine. Many physicians in the department serve in major professional societies. The department is well-known at home and abroad for its strong clinical strength and advanced surgical technology. It has a domestic first-class and internationally leading professional colorectal tumor surgery team. It attracts a large number of patients from the city and other places every year. The annual operation volume reaches 1,200, of which colorectal cancer surgery accounts for more than 90%. It has maturely carried out a variety of minimally invasive surgical methods including traditional laparoscopy, robots (Da Vinci), etc., to reduce patient pain and shorten hospitalization time. The department emphasizes standard total mesocolectomy (CME) and total mesorectal excision (TME). The standard and thorough resection range can not only make the patient's pathological staging more accurate, but also provide an important basis for formulating a more precise and individualized comprehensive treatment plan after surgery, and can also improve the patient's prognosis. The department also has unique advantages in low rectal surgery. Ultra-low anus-preserving radical rectal cancer surgery avoids the inconvenience caused by fistula. The pelvic autonomic nerve is preserved during radical rectal cancer surgery, which not only achieves the purpose of radical cure, but also preserves sexual function, greatly improving the patient's quality of life. The department's standardized treatment and patient prognosis are in a leading position in the country, and it has also participated in the formulation of national standardized treatment standards for colon and rectal cancer. The department adheres to the Multidisciplinary Team Consultation (Multiple Disciplinary Team, MDT) system for special and difficult cases of colorectal tumors, holds regular seminars, and invites experts from multiple related disciplines such as surgical oncology, medical oncology, radiotherapy, imaging, and pathology to discuss together. Based on a detailed discussion of each patient's condition, targeted treatment measures are adopted to achieve the purpose of receiving an individualized treatment plan. Conversion therapy has increased the surgical resection rate of metastatic colorectal cancer. At the same time, radiofrequency ablation, CyberKnife and other treatment methods combined with it have greatly improved the radical cure rate and survival rate of patients with metastatic colorectal cancer. Neoadjuvant concurrent chemoradiotherapy not only improves the anus-preserving rate for patients with low rectal cancer, but also reduces the postoperative recurrence rate and improves the patient's quality of life. While actively completing a large amount of clinical work, the department strives to carry out clinical and basic research on colorectal tumors, presides over and completes two National Natural Science Foundation projects, more than ten projects at provincial, ministerial, bureau and school levels, and participates in more than ten domestic large-scale prospective multi-center clinical studies. It publishes SCI collections every year. He has published more than ten papers in core journals, participated in the compilation of many academic monographs such as "Abdominal Oncology" and "Tumor Surgery", and presided over the research on "Functional Continuous Jejunal Interposition Gastric Replacement Surgery" and "Total Gastrectomy and Digestive Tract Reconstruction", and won the second prize of the National Science and Technology Progress Award and the third prize of the Tianjin Science and Technology Progress Award respectively. The department is committed to continuously improving discipline construction, driving discipline progress, enhancing influence in the industry, and always contributing to the overall development of the hospital. View full introduction

Gastric Tumor Department›

The Department of Gastric Oncology of Tianjin Medical University Cancer Hospital was established in 2004. It was formerly the Department of Abdominal Oncology. Professor Zhang Tianze, the first chairman of the Chinese Anti-Cancer Association, and Academician Hao Xishan, the third chairman of the Chinese Anti-Cancer Association, are both professors of the Department of Abdominal Oncology. The first department director was Professor Zhang Tianze, and the second department director was Professor Wang Dianchang. In 1999, the original Department of Abdominal Oncology was divided into the Department of Gastrointestinal Oncology and the Department of Hepatobiliary Oncology, with Professor Wang Jiacang serving as the Director of the Department of Gastrointestinal Oncology. In 2004, the Department of Gastrointestinal Oncology was divided into the Department of Gastric Oncology and the Department of Colorectal Oncology, with Professor Liang Han serving as the Director of the Department of Gastric Oncology. Since the establishment of the Department of Gastric Oncology, with the joint efforts of general medical staff, a comprehensive treatment model focusing on surgical treatment of gastric cancer has gradually been formed. It ranks among the top in the country in terms of standard surgery for gastric cancer, hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer, and digestive tract reconstruction after gastrectomy. Currently, it is the designated chairman unit of the Gastric Cancer Professional Committee of the Chinese Anti-Cancer Association, the designated chairman unit of the Oncology Surgery Professional Committee of the Chinese Medical Association, the deputy chairman unit of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology, and the deputy chairman unit of the Gastrointestinal Stromal Tumor Professional Committee of the Chinese Anti-Cancer Association. Since the MDT multidisciplinary diagnosis and treatment model for gastric cancer was established in 2012, more than 60 MDT consultations have been organized so far, and more than 1,000 difficult cases have been consulted. Patients come from more than 20 provinces and cities across the country. Since 2007, the MDT multidisciplinary diagnosis and treatment of gastric cancer in Tianjin has been organized and completed 5 times. In recent years, more than 20 remote MDT case discussions have been organized. Received more than 100 MDT studies and surgical observations from other hospitals, involving more than 100 people. It is the gastric cancer standard training demonstration base of the Chinese Anti-Cancer Association. Since the China-Japan-Korea Gastric Cancer Tianjin Summit was organized in 2012, it has been held 4 times. The 3rd Gastric Cancer Tianjin Summit was held. There are currently 16 doctors in the department, including 10 with doctorate degrees, 5 with doctorate degrees, and 1 with a master's degree. There are 4 chief physicians and 6 deputy chief physicians; There is 1 attending physician and 4 resident physicians. There are 3 tutors for master’s degree students. Since its establishment in 2004, it has presided over more than 20 scientific research projects of various types, trained more than 30 graduate students, and published more than 300 papers, including more than 100 SCI papers. Published 6 monographs including "Gastric Cancer" and "Photographs of Radical Surgery for Gastric Cancer". The "Total gastrectomy with continuous interposition of jejunum to replace the stomach" project chaired by Academician Hao Xishan won the second prize of the National Science and Technology Progress Award. The project "Creation and Application of Key Technologies of Comprehensive Gastric Cancer Prevention and Treatment System" jointly conducted by our department and Peking University Oncology and other units won the first prize of the Chinese Medicine Award in 2016, the first prize of the National Ministry of Education and the second prize of the National Science and Technology Progress Award in 2017. View full introduction

Pathology Department›

The Pathology Department of Tianjin Medical University Cancer Hospital was founded in the 1950s by Professor Wang Deyan, a famous tumor pathologist. It is now a key clinical specialty construction unit, an affiliated unit of Tianjin Difficult Pathology Consultation Center and Pathology Quality Control Center, a training base for pathologists in Tianjin, a training site for postdoctoral, doctoral and master's degree students in pathology at Tianjin Medical University, and the organizer of the "National Training Course for Oncology Pathologists". In terms of pathological diagnosis, scientific research and teaching of tumors, it ranks first in Tianjin and at the domestic advanced level. There are currently 48 staff in the department, including 22 physicians (4 chief physicians and 7 deputy chief physicians), 17 with doctorate degrees, and 8 with overseas study experience. There are 2 doctoral supervisors and 4 master supervisors. There are 3 talents with the title of provincial and ministerial level or above, 1 deputy chairman and 3 standing committee members of the national second-level society. It has been committed to the construction of pathology subspecialties for many years. At present, it has established multiple tumor pathology subspecialties such as lymphatic blood, thyroid, respiratory system and mediastinum, bone and soft tissue, stomach and pancreas, colorectum and liver, genitourinary system and cytology. Each subspecialty is led by at least one deputy chief physician. In 2014, a molecular pathology diagnostic laboratory was established. The number of difficult pathological consultations increases year by year, covering more than a dozen provinces, municipalities and autonomous regions, mainly in the north and northwest. In particular, the pathological diagnosis of lymphatic and hematopoietic tumors has formed a regional advantage, and patients come from all over the country. He also participated in the formulation of many domestic tumor pathology diagnosis guidelines and standards. In the past five years, he has won 21 scientific research projects at all levels, including 8 national scientific research projects. He has published 53 SCI-indexed papers as the first author/corresponding author, of which 10 have a score of 5 or above, and the highest impact factor is 23.893 (CancerCell). The "National Oncology Pathologists Training Class" hosted by the Department of Pathology has been held for 35 consecutive years, training hundreds of oncology pathologists from all over the country, many of whom have become leaders and business backbones of the pathology departments of their hospitals. View full introduction

Integrative Medicine Department›

The Department of Integrated Traditional Chinese and Western Medicine at Tianjin Medical University Cancer Hospital was founded in 1978 and is one of the domestic medical teaching and research bases for integrated traditional Chinese and Western medicine oncology. As a traditional department of the hospital, after 40 years of hard work by several generations, the Department of Integrated Traditional Chinese and Western Medicine has become a well-known research team in the country for the comprehensive prevention and treatment of tumors using traditional Chinese and Western medicine. The undergraduate department is the master's degree authorization point of Tianjin Medical University, and is an anti-tumor drug trial institution and dependence drug clinical trial institution recognized by the Ministry of Health and the State Food and Drug Administration. In 2012, it was rated as “the first batch of demonstration wards for standardized treatment of cancer pain by the Ministry of Health”. The ward has 90 beds and currently has 18 medical professional technicians, 2 chief physicians, 4 deputy chief physicians, 7 attending physicians, 1 lecturer, 1 assistant researcher, and 3 physicians, including 9 doctors; Master's degree: 4 people, training more than 10 master's degree students. A good talent echelon has been formed to ensure the sustainable development of the discipline. Under the leadership of the current academic leader, Chief Physician Pan Zhanyu, the department has gathered a group of outstanding young and middle-aged experts in integrated traditional Chinese and Western medicine oncology. Four treatment groups have been established based on academic expertise: lung cancer, breast cancer, digestive tract tumors, and hepatobiliary and pancreatic tumors. Senior academic leaders in each department are responsible for carrying out medical, teaching, and research work on related diseases, and have formed relatively mature diagnosis and treatment standards for integrated traditional Chinese and Western medicine. The department has established a special TCM outpatient clinic based on disease classification, giving full play to the advantages of traditional medicine to facilitate cancer patients' treatment. It also regularly conducts patient education lectures in the outpatient clinic to popularize knowledge about cancer prevention and anti-cancer. In 2017, the department had more than 39,600 outpatient visits and more than 3,500 hospitalizations, of which 33% were patients from other places. Department features Through more than 30 years of clinical experience and nearly 20 years of experimental research, the Department of Integrated Traditional Chinese and Western Medicine has summarized a complete and effective set of experience in treating tumors with integrated traditional Chinese and Western medicine. It has successively developed a variety of pure Chinese medicine anti-cancer preparations, and has maturely carried out technical projects such as spectrum intervention percutaneous penetration of Chinese medicine for cancer pain treatment, Chinese medicine fumigation technology for nerve injury treatment, low-frequency pulsed magnetic field treatment for osteoporosis, three-dimensional moxibustion, Chinese medicine hyperthermia, linear polarized infrared therapy, high-pressure atomized inhalation Chinese medicine treatment and other technical projects. The tongue and pulse comprehensive tumor evaluation system is used in the diagnosis and treatment process, which plays an important role in the multidisciplinary comprehensive treatment of tumor patients. (1) Integrating traditional Chinese and Western medicine to prevent tumor recurrence and metastasis: After most surgeries, chemotherapy, and radiotherapy, cancer patients enter a "waiting" stage. Western medicine no longer performs any treatment, and only requires regular review until the tumor recurs or metastasizes before adopting corresponding treatments. This "waiting" stage is a good period for traditional Chinese medicine to give full play to its advantages. Based on the principle of "Yin Ping Yang Secret", we use holistic treatment combined with local treatment, and organically combine disease differentiation treatment with syndrome differentiation treatment, which will greatly reduce the chance of recurrence and metastasis of tumor patients and significantly extend the survival period of patients. (2) The combination of acupuncture and medicine combined with surgery, radiotherapy and chemotherapy can reduce toxicity, increase efficiency and accelerate recovery: As the main treatment methods of modern medicine, surgery, chemotherapy and radiotherapy have an irreplaceable position in tumor treatment. However, while treating tumors, both radiotherapy and chemotherapy have inevitable toxic side effects. Properly supplemented with traditional Chinese medicine and acupuncture, it can not only reduce toxicity and increase effectiveness, but also protect normal immune function and minimize damage; Multidrug resistance to chemotherapy drugs can be solved to a certain extent; And it can increase the sensitivity of radiotherapy and chemotherapy; The department combines syndrome differentiation treatment with dialectical care, and combines acupuncture with traditional Chinese medicine. During the recovery period after surgery and the gap period between radiotherapy and chemotherapy, the trauma of surgery, radiotherapy and chemotherapy is repaired as soon as possible, and the adverse reactions during the peri-radiotherapy and chemotherapy period are reduced. (3) Multidisciplinary joint treatment of refractory tumors: The department team has established a multidisciplinary joint diagnosis and treatment team with departments such as imaging, radiotherapy, pathology, and surgery, and regularly conducts palliative care MDT outpatient clinics. For complex and refractory tumor diseases, comprehensive diagnosis and treatment is carried out through multidisciplinary joint discussions, giving full play to the advantages of traditional Chinese medicine, and truly achieving "human-tumor coexistence." At the same time, the department has rich experience in the comprehensive treatment of targeted drugs, anti-vascular drugs, and immune-targeted drugs, as well as the treatment of toxic and side effects of targeted drugs with traditional Chinese and Western medicine. (4) The concept of "treating diseases before they occur" and reversing precancerous lesions: According to the principle of "preventing disease before it becomes a disease, and preventing disease before it becomes a disease", early application of traditional Chinese medicine to treat and intervene precancerous lesions such as atrophic gastritis, liver cirrhosis, cystic breast hyperplasia, cervical erosion, mucosal leukoplakia, chronic ulcerative colitis, etc. Not only will the symptoms be significantly improved, but the risk of cancer can also be significantly reduced. teaching As the master's degree authorization point of Tianjin Medical University, the undergraduate department has not only trained more than 10 outstanding master's students, but also extensively participated in domestic and foreign technical exchanges and cooperation. At the same time, it has accepted many domestic and foreign scholars to come to the department for exchanges, including 1 visiting scholar from India, trained 1 Dutch exchange graduate student, and has received many foreign delegations to visit the department and study. research The Department of Integrated Traditional Chinese and Western Medicine has undertaken nearly 30 national natural science foundation, Tianjin Municipal Science and Technology Commission key projects, Tianjin Municipal Health Bureau projects and national new cancer drug research projects. "Painless Cancer in 2000" won the Outstanding Achievement Award. In 1997 and 2003, "Standardized Treatment of Pain" won the bid for the Ministry of Health's continuing medical education project. In recent years, many projects have been funded by the China Traditional Chinese Medicine Cancer Research Fund and the CSCO-TCM Cancer Research Fund. In the past five years, he has published more than 50 papers, including more than 10 papers included in SCI, and has obtained 2 national invention patent authorizations. He is the editor-in-chief of "Clinical Cancer Pain Therapeutics" and co-editor of many books such as "Hepatitis B Research Advances", "Concise Oncology", "Abdominal Oncology", "Guidelines for the Diagnosis and Treatment of Clinical Oncology in Traditional Chinese Medicine", "Tumor Palliative Supportive Treatment Tutorial" and other books. In March 2011, he took the lead in launching a public welfare survey on cancer pain epidemiology for cancer patients in all secondary and tertiary hospitals in eight provinces and cities in northern China - "Operation Spring". It has had a huge impact in the academic world and made a significant contribution to the epidemiological survey of pain. It was awarded by the Department of Medical Affairs of the Ministry of Health. In 2017, he took the lead in establishing the Regional Alliance for Integrated Traditional Chinese and Western Medicine oncology, which promoted the development of integrated traditional Chinese and Western medicine oncology in Tianjin and was well received by the industry. Main research topics: 1. Eleventh Five-Year National Science and Technology Support Plan: Research on Comprehensive Traditional Chinese Medicine Treatment Program for Non-Small Cell Lung Cancer. State Administration of Traditional Chinese Medicine No.: 2006BAI04A05; 2. Study on the time-effect relationship of Xiaoyan decoction in attenuating and enhancing the efficacy of chemotherapy for non-small cell lung cancer with Qi deficiency, poison stasis type. Tianjin Municipal Science and Technology Commission’s key science and technology support project number: 07CGYSF00900; 3. Based on the LPS-mediated TLR4/MyD88/NF-κB pathway, National Natural Science Foundation Youth Project to explore the mechanism of Agreement No. 1 prescription in the treatment of nasopharyngeal carcinoma; 4. Based on the JAK2/STAT3/WASF3 signaling pathway, explore the mechanism of Qingyi Huaji Recipe in inhibiting the invasion and metastasis of pancreatic cancer. National Natural Science Foundation of China Youth Project; 5. Research on the mechanism of liver cancer protocol to reverse NK cell dysfunction in the treatment of hepatitis B-related liver cancer National Natural Science Foundation of China Youth Project; 6. Study on the fine structure, molecular modification, anti-tumor effect and mechanism of Cordyceps polysaccharide. Key project of Tianjin Science and Technology Commission’s applied basic and cutting-edge technology research plan; 7. Clinical study on the relationship between genetic polymorphisms and traditional Chinese medicine in preventing irinotecan delayed diarrhea. Scientific research project of the Traditional Chinese Medicine Division of Tianjin Municipal Health Bureau; 8. Study on the role and mechanism of Jiedu Quyu Recipe in affecting the proliferation, apoptosis, metastasis and invasion of human breast cancer cells. Scientific research project of the Traditional Chinese Medicine Division of Tianjin Municipal Health Bureau; 9. Explore the anti-angiogenic effect of astragalus saponins in the treatment of colon cancer based on the HIF pathway. Scientific research project of the Traditional Chinese Medicine Division of Tianjin Municipal Health Bureau; 10. Explore the anti-lung cancer mechanism of Yifei Qinghua Cream based on the PD-L1/PD1 pathway. Scientific research project of the Traditional Chinese Medicine Division of Tianjin Municipal Health Bureau; 11. Phase II multi-center randomized controlled study of Yuhuai Anchang Decoction in the prevention and treatment of radiation enteritis. Scientific research project of the Traditional Chinese Medicine Division of Tianjin Municipal Health Bureau; 12. Discussion on the full intervention model for patients with lung cancer receiving gefitinib targeted therapy. College-level topics; 13.Clinical significance of Ezrin in colorectum. College-level topics; 14. Experimental study on the treatment of pancreatic cancer with Cinobufoxin combined with gemcitabine. College-level topics; 15. Study on the mechanism of ginsenoside Rg3 regulating resistance to anti-vascular therapy. College-level topics; 16. Study on the mechanism of drug resistance reversal by compound Sophora flavescens injection. College-level topics; 17. Study on the anti-angiogenesis mechanism of Xiaoji Recipe based on VEGF/VEGFR2. CSCO Horizontal Fund. View full introduction

Maxillofacial Otolaryngology Tumor Department›

The Department of Maxillofacial Otolaryngology Oncology of Tianjin Medical University Cancer Hospital inherited the Department of Head and Neck Oncology founded by Professor Li Shuling, the founder of head and neck cancer in my country. At the end of 2004, in order to meet the needs of department construction and discipline development, the Department of Head and Neck Oncology was divided into two independent departments. Head and neck surgery experts Professor Zhang Lun, Professor Wang Xudong, Director Xu Benyi, Director Zhang Wenchao, Director Jin Rui and Director Tao Yingjie continue to engage in medical work in the Department of Maxillofacial Otolaryngology Oncology. On the basis of inheriting the medical and technical characteristics of the original Department of Head and Neck Oncology, the Department of Maxillofacial Otolaryngology Oncology has continuously made breakthroughs and innovations through continuous technological improvement and innovation, forming a domestically leading and internationally first-class head and neck tumor diagnosis and treatment team. Currently, there are 93 actual beds and 59 medical staff, including 3 chief physicians, 6 deputy chief physicians and 8 attending physicians. There are 2 resident doctors and 1 scientific researcher. Among them, 1 is a “Young Top-notch Talent” from the Tianjin Talent Development Special Support Program; There is 1 member of Tianjin’s “131” innovative talent team, 1 deputy chairman of the Nasopharyngeal Cancer Professional Committee of the Chinese Anti-Cancer Association, 1 deputy chairman of the Thyroid Cancer Professional Committee of the Tianjin Anti-Cancer Association, 2 standing committee members of the Head and Neck Professional Committee of the Chinese Anti-Cancer Association, 1 standing member of the Thyroid Cancer Professional Committee of the Chinese Anti-Cancer Association, 1 deputy chairman of the Youth Committee of the Head and Neck Professional Committee of the Chinese Anti-Cancer Association, 1 member of the Youth Committee of the Head and Neck Professional Committee of the Chinese Anti-Cancer Association, and a standing committee member of the Tianjin Branch of the Microsurgery Committee of the Chinese Medical Association. The Department of Maxillofacial Otolaryngology Oncology specializes in the surgical resection of benign and malignant tumors of the oral cavity, maxillofacial region, otolaryngology, thyroid gland, and other head and neck tumors, and the comprehensive treatment of mid- and late-stage head and neck malignant tumors. It focuses on salvage surgeries for advanced and recurrent malignant head and neck tumors and plastic repair of large area defects after resection. The core technologies of the department include preoperative induction chemotherapy for mid-to-late stage head and neck squamous cell carcinoma, various partial laryngeal surgeries that preserve laryngeal function, hypopharyngectomy, voice reconstruction after total laryngectomy, multifunctional cervical lymph node dissection, microsurgical repair, laparoscopic minimally invasive surgical treatment (direct laryngoscope, nasal endoscope, laparoscopic-assisted and da Vinci robotic surgery), planned arterial resection and reconstruction surgery, etc. It focuses on radical tumor cure, functional preservation and repair and beauty, which greatly improves patient survival and quality of life. While actively doing clinical work, he is committed to basic research on head and neck squamous cell carcinoma, exploring new targets for anti-head and neck squamous cell carcinoma treatment, achieving medical transformation, and improving patient survival. At present, the department has won 7 National Natural Science Foundation projects, 2 National Key Specialty Construction Projects, 1 National Cancer Clinical Center project, and more than 10 provincial, ministerial, bureau-level and school-level projects; The leading department took the lead in carrying out 3 clinical trials to provide evidence-based evidence to solve practical clinical problems and guide the clinical treatment of diseases. He has published more than 40 SCI papers and more than 100 papers in core journals in Naturecommunication, Clinicalcancerresearch, Cancerletters, MolecularCancerTherapeutics and other magazines. In addition, the Department of Maxillofacial Otorhinolaryngology Oncology is responsible for the teaching of oncology postgraduate students at Tianjin Medical University and the training courses for oncologists across the country. Currently, the department has 2 doctoral supervisors and 3 master's students. It recruits 110-12 doctoral and master's students and 10-14 training doctors every year. He has edited and participated in the editing of many books in the field of head and neck tumors, including "Head and Neck Oncology", "New Head and Neck Oncology", "Head and Neck Oncology Third Edition", "Oral and Maxillofacial Oncology", "Head and Neck Oncology and Surgical Repair", "Oncology Surgery", "Head and Neck, Intracranial and Spinal Canal Oncology", and participated in the formulation of "Comprehensive Treatment of Head and Neck Squamous Carcinoma: Chinese Expert Consensus 2013 Edition" and "Expert Consensus on Diagnosis and Treatment of Papillary Thyroid Carcinoma (2016 Edition)". At the same time, the Department of Maxillofacial Otorhinolaryngology Oncology actively engages in exchanges and cooperation with many well-known foreign cancer research centers. Established long-term cooperation and exchanges with international organizations in the field of head and neck tumor surgery and basic research, and jointly completed multiple cases of difficult surgeries and MDT diagnosis and treatment of head and neck squamous cell carcinoma; Jointly established an MDT diagnosis and treatment project for mid-to-late stage head and neck squamous cell carcinoma with the Taiwan Head and Neck Oncology Society to achieve regular mutual visits and exchanges; In terms of oral and maxillofacial restoration, we have established long-term training and exchange relationships with Zhongshan Stomatological Hospital and Shanghai No. 9 Hospital. View full introduction

Esophageal Tumor Department›

The Department of Esophageal Oncology of Tianjin Medical University Cancer Hospital is a professional department developed and established on the basis of the professional thoracic tumor treatment group established in my country. It is now the seat of the chairman unit of the Esophageal Cancer Professional Committee of the Chinese Anti-Cancer Association. In 2012, it was rated as a national key specialty in thoracic surgery by the Ministry of Health. Currently, the department director, Professor Yu Zhentao, serves as the academic leader and serves as the chairman of the Esophageal Cancer Professional Committee of the Chinese Anti-Cancer Association and the chairman of the Tianjin Esophageal Cancer Professional Committee. The Department of Esophageal Oncology not only inherits the superb surgical skills and rigorous work attitude of the older generation of medical workers, but also inherits the nationally renowned medical characteristics of the original Thoracic Surgery Department. The Department of Esophageal Oncology currently has 80 beds and 15 professional and technical staff, including 4 chief physicians and 5 deputy chief physicians; There is 1 doctoral supervisor, 9 doctoral students, and 4 master's students. According to statistics, in 2017, there were more than 9,960 outpatients, more than 1,600 inpatients, and 500 thoracic surgeries of various types were completed. The Department of Esophageal Oncology is good at the diagnosis and treatment of thoracic tumors, and performs routine radical esophageal cancer surgery, lung cancer surgery, cardia cancer radical surgery and mediastinal tumor resection. Minimally invasive surgery was carried out earlier, and now the technology is mature, including thoracoscopy, laparoscopy and da Vinci robotic surgery. The proportion of minimally invasive surgery has reached 80%. It attaches great importance to the standardized dissection of regional lymph nodes. In addition, it is a national leader in preoperative neoadjuvant therapy and postoperative nutritional therapy. It regularly holds standardized training courses and has been recognized and praised by peers. At the same time, it has also achieved a lot of achievements and valuable experience in the comprehensive treatment of esophageal cancer, cardiac cancer, lung cancer and mediastinal tumors. It has established good collaborative relationships with relevant departments in many centers across the country, and has led and participated in a number of domestic prospective clinical studies to ensure reasonable treatment of patients and achieve good results. While actively doing clinical work, the undergraduate department has also conducted a large amount of basic research, undertaken 3 National Natural Science Foundation projects, and has many other research projects at all levels. It has won a number of national, provincial and ministerial level awards, has published more than 200 articles in SCI magazines and domestic core professional journals, and has trained more than 30 doctoral and master's degree graduate students. In recent years, hundreds of training doctors from all over the country have been trained, and they are playing an active role in their respective jobs. View full introduction

Interventional Therapy›

The Interventional Therapy Department of Tianjin Medical University Cancer Hospital was formally established in June 2001 on the basis of the original Interventional Group of Radiology Department, and is a first-level clinical department. The discipline has independent wards with 69 open beds, as well as outpatient clinics, interventional operating rooms, and minimally invasive treatment rooms. The main equipment includes digital subtraction angiography machine, argon-helium ultra-low temperature freezing system, CT, ultrasonic diagnostic equipment, etc. The discipline has outstanding features in the treatment of benign and malignant tumors and their comorbidities. The treatment concept is "single disease, multi-disciplinary, and multi-technical comprehensive treatment of tumors", and the development goal is "minimally invasive, efficient, and low toxicity." Super-selective target vessel embolization is used to treat benign tumors such as liver and limb hemangiomas, uterine fibroids, and adenomyosis. Ultrasound-guided percutaneous puncture of liver and kidney cysts is treated with drug inactivation. The efficacy is remarkable or the purpose of radical surgical cure can be achieved. Selective arterial embolization chemotherapy combined with "argon-helium knife" ultra-low temperature cryo-targeted treatment of primary and secondary malignant tumors of the head and neck, chest, abdomen, pelvis and limbs. For the comorbidities caused by benign and malignant tumors, such as: tracheal stenosis, tracheoesophageal fistula, trachepleural fistula, esophageal stenosis, duodenal stenosis, obstructive jaundice, superior vena cava syndrome, Budd-Chiari syndrome, gastrointestinal bleeding, portal hypertension, hepatic arterial portal fistula, deep vein thrombosis of the lower limbs, tumor rupture and bleeding, spinal bone metastasis caused by malignant tumors, etc., corresponding palliative interventional symptomatic treatment is accurate and effective. Outstanding achievements and important innovations include argon-helium cryotherapy combined with interventional treatment of solid mesenchymal tumors that are insensitive to radiotherapy and chemotherapy, clinical research on argon-helium cryotherapy for early-stage prostate and T3/T4 stage hormone-independent prostate cancer, and applied basic research on the relationship between malignant tumor load and host cell immune function, immune response after argon-helium cryotherapy for localized prostate cancer, and tumor vaccine development. In terms of scientific research and teaching, the discipline has undertaken 2 National Science and Technology Support Plan projects, 4 National Natural Fund projects, 1 Twelfth Five-Year Plan project for the "Major Science and Technology New Drug Creation" Science and Technology Major Project, 2 Tianjin Major Anti-cancer Special Research Plans, 1 Tianjin Key Applied Basic Research Project, 2 Tianjin Natural Science Fund-funded projects, 2 Wu Jieping Medical Foundation Clinical Research Special Fund Projects, 4 Tianjin Municipal Health Bureau Scientific Research Fund and other scientific research projects. He has presided over 5 multi-center clinical registration experimental studies, and has won 5 provincial first, second, and third-level scientific and technological achievement awards. He has published more than 90 papers in domestic core journals, 20 of which are included in SCI. He has edited 1 monograph and participated in the editing of 8 monographs. It has trained more than 10 doctoral students and more than 30 master's students. Currently, there are 1 professor, 4 chief physicians, 5 deputy chief physicians, 4 attending and resident physicians, 8 are currently studying for PhDs, and 7 are masters. View full introduction

Urology Oncology›

The Department of Urology Oncology of Tianjin Medical University Cancer Hospital was formerly the Department of Pelvic Urology Oncology of Tianjin Cancer Hospital with a history of 60 years, founded by Professor Jin Jiarui. During the "Tenth Five-Year Plan" period, in order to meet the needs of cancer patients, optimize the layout of disciplines, and refine the professional layout, the hospital reorganized the Department of Urological Oncology, with Professor Yao Xin as the department director. After years of development, the department has grown from 6 physicians at the time of its inception to 15 physicians now, including 5 chief physicians, 2 deputy chief physicians, 1 postdoctoral fellow, and 7 with doctorate degrees. The discipline has gradually formed the characteristics of a systematic and standardized treatment of urological and male reproductive system tumors based on surgical treatment, combined with comprehensive treatment models such as radiotherapy, chemotherapy and targeted therapy. Department Director Yao Xin, MD, postdoctoral fellow, chief physician, master's tutor, member of the Urology Branch of the Chinese Medical Association, and deputy director of the Genitourinary Tumor Professional Committee of the Chinese Anti-Cancer Association. The department is currently divided into three major treatment groups: bladder cancer, kidney cancer, and prostate cancer, all of which are composed of old, middle-aged and young people. Specialized outpatient clinics for prostate cancer, kidney cancer, and bladder cancer are opened on Monday, Wednesday, and Thursday afternoons respectively. In order to give full play to the technical characteristics of various related disciplines in the cancer hospital, the Department of Urology has also established a multidisciplinary joint consultation platform including urology department, pathology department, imaging center, radiotherapy department, interventional department, medical oncology department and biotherapy center, and carried out cold treatment of prostate cancer and kidney cancer. Clinically practical technical methods include cryotherapy and interventional therapy, CyberKnife treatment of metastatic urological tumors, diagnosis and surgical treatment of early bladder cancer guided by narrow-band spectral imaging (NBI), and research on bladder preservation strategies for invasive bladder cancer under the guidance of adjuvant and neoadjuvant chemotherapy. On the basis of inheriting the "sharp resection" tradition of radical oncology surgery of the older generation, the department has adapted to the new characteristics of tumor onset and the new needs of tumor patients, and has successively carried out and improved a number of new surgeries featuring minimally invasive, functional preservation and reconstruction, including laparoscopic radical nephrectomy, partial nephrectomy, renal pelvis cancer, ureteral cancer radical resection, adrenalectomy, etc. With the introduction of the da Vinci robot in the hospital, it has also actively carried out various robot-assisted urological surgeries. Nephron-sparing surgery is one of the specialty surgeries of the department. In addition to inheriting traditional surgical techniques, it also performs renal segmental artery occlusion and "zero ischemia time" partial nephrectomy. In order to standardize and improve the safety of partial nephrectomy surgery, the department has launched a number of clinical studies. By introducing the nephron-sparing surgery safety scoring system and combining it with imaging tumor risk assessment, the selective indications for nephron-sparing surgery have been extended to some patients with stage Ib or even stage II renal cancer. Through follow-up research on the safety of resection margins, the concept of safe resection margins in nephron-sparing surgery was proposed. Among more than 300 nephron-sparing surgeries performed in the past five years, the follow-up local recurrence rate was 0.5%, which is far lower than the recurrence level reported in the literature. The "Study on the Safe Resection Range of Nephron-Sparing Surgery" conducted by Chen Xusheng et al. reported the safe resection margin of partial nephrectomy for T1b stage renal cancer, and was accepted for publication in Urology magazine. In terms of basic research, it currently undertakes 4 National Natural Science Foundation projects and 1 National Oncology Clinical Research Center project, and has published more than 30 SCI-collected papers in foreign magazines. Through the efforts of the department's doctors, we also have a complete renal cancer tissue specimen bank. Cooperate with international centers to carry out multiple collaborative research including kidney cancer gene chip research, pathological subtyping, etc. In the past few years, relying on the National Pharmacology Clinical Base, it has participated in international multi-center clinical trials of a variety of drugs, making contributions to research in new fields of tumor treatment. Drawing on the long culture of Tianjin Medical University Cancer Hospital with a history of more than 150 years, and adhering to the hospital motto of high ethics and high ethics, advocating innovation and perfection, the Department of Urological Oncology of Tianjin Medical University Cancer Hospital is facing the challenges of the future with a new look. View full introduction

Radiology Department›

The Radiology Department of Tianjin Medical University Cancer Hospital was founded in 1930 and is the earliest professional radiation medicine department established in my country. After several generations of unremitting efforts and hard work, the department has a high reputation and influence in the domestic imaging and oncology circles. It is at the domestic leading level in certain fields such as the diagnosis of body tumor diseases and the rapidly developing radiomics and medical imaging functional imaging technology in recent years. The department has a complete range of imaging equipment. With the increasingly complete imaging equipment and the continuous improvement of medical imaging technology, the number of examination services provided to patients has increased year by year, exceeding 280,000 in 2017. In 1992, the Tianjin Medical Imaging Center was established with the approval of the Tianjin Municipal Health Bureau and is located in the Radiology Department of our hospital. Since 1994, it has organized well-known experts in the field of imaging in Tianjin to come to the hospital for consultation every Thursday morning. Since its establishment, it has helped organize collective consultations on the imaging data of more than 12,000 patients with difficult rare diseases from all over the country, of which more than 50% are patients from other places. It not only solves the patient's difficulty in seeking medical treatment, but also buys valuable treatment time for tumor patients, winning widespread social praise. The Department of Radiology is an imaging discipline that takes clinical care as the main body and integrates the comprehensive development of medicine, teaching, research, and prevention. The key direction of the discipline is radiomics of common malignant tumors; Clinical application of cone beam breast CT; Low-dose CT screening for lung cancer; Construction of imaging platform for comprehensive drug clinical evaluation; MRI, CT functional imaging and energy spectrum imaging, etc. Covering malignant tumor screening, early diagnosis, diagnosis and identification of benign and malignant tumors, tumor staging, efficacy evaluation, recurrence monitoring, prognosis evaluation, etc. Provide strong support for clinical diagnosis and treatment. There are currently 77 staff members, including 36 doctors, including 11 doctors and 21 masters. 1 doctoral supervisor, 1 outstanding young innovative person, 1 outstanding young teacher in Tianjin universities, and 2 college-level new century talents; There is one candidate for the chairmanship of a national academic group. In the past three years, he has hosted or participated in more than 10 key R&D projects of the Ministry of Science and Technology, the National Natural Science Foundation and international scientific and technological cooperation, and more than 20 projects at the Tianjin Science and Technology Commission, Health and Family Planning Commission, Tianjin Medical University and hospital level projects. Published more than 30 SCI papers. In 2017, he received funding from the “Thirteenth Five-Year Plan” Comprehensive Investment Discipline Construction Project of Tianjin Medical University Cancer Hospital. At the same time, he undertakes the teaching tasks of Tianjin Medical University’s medical and imaging majors and the national oncologist training class. Each year, we recruit 4-5 doctoral and master's degree students in imaging majors. Every year, 40-50 undergraduates from Tianjin Medical University and Mudanjiang Medical College receive training from various regions, standardized training for residents, and interns. View full introduction

Bone and Soft Tissue Tumor Department›

The Department of Bone and Soft Tissue Oncology of Tianjin Medical University Cancer Hospital was founded in 1979 to train a large number of specialist talents for domestic cancer hospitals. It is a specialty bone and soft tissue tumor specialty integrating surgery, functional rehabilitation, psychological treatment and nursing. The director of the department was Zhang Yunxiang, followed by Song Jingang and Fang Zhiwei. Since 2008, Wang Guowen, a postdoctoral fellow in bone tumors, has been the director of the department. Under the leadership of director Wang Guowen, it has become routine for the department to perform total vertebral resection and reconstruction, total sacrum resection and reconstruction, and hemipelvic resection and reconstruction. The department's advantage has always been in the resection and reconstruction of giant soft tissue tumors. The department currently has 2 doctoral supervisors (Wang Guowen), 2 chief physicians, 5 deputy chief physicians, 5 attending physicians, and 2 lecturers, including 7 with doctorate degrees, 3 with master's degrees, 1 rehabilitation therapist, and 1 psychotherapist. In 2017, the department had 16,448 outpatient visits, treated 1,972 patients annually, and performed 1,233 surgeries. Director Wang Guowen has been in charge of the work for 10 years, and the department has made great progress. The department is a member of the Tianjin Anti-Cancer Association's Bone and Soft Tissue Tumor Specialty, and the Tianjin Medical Doctors Association's Bone Tumor Specialty Chairman Unit. Director Wang Wangowen has academic part-time positions in many academic organizations such as the Bone Oncology Group of the Orthopedic Branch of the Chinese Medical Association, the Sarcoma Professional Committee of the Chinese Anti-Cancer Association, and the Chinese Medical Doctors Association, and is a member of the World Limb Salvage Society (ISLOS). Director Wang Guowen is one of the earliest researchers in China to study the mechanism of dedifferentiated chondrosarcoma. He has conducted research on radiofrequency ablation-assisted open surgery for the treatment of spinal tumors, and gave a speech in this regard at the 19th World Limb Salvage Congress held in Kanazawa, Japan, in 2017. In recent years, he has undertaken 2 international cooperation projects, 5 National Natural Science Foundation projects, 3 provincial and ministerial level projects, 2 Tianjin Municipal Science and Technology Commission projects, 2 Tianjin Municipal Education Commission projects, 2 Tianjin Medical University projects and 4 hospital-level projects. He has published more than 80 papers in domestic and foreign journals, which are included in SCI He has 33 articles with the highest impact factor of 8.791 and a cumulative impact factor of more than 80 points. He has won two third prizes of the Municipal Science and Technology Progress Award, one first prize and one second prize of the Tianjin Medical University Science and Technology Award. He has compiled "Modern Surgical Treatment of Soft Tissue Sarcoma" and "English-Chinese-Chinese Orthopedic Glossary". Participated in the compilation of "New Practical Orthopedics", "Physical Examination of Spine and Extremities", "Clinical Diagnosis of Bone and Joint Diseases", "Tumor Surgery", "Concise Oncology", "Practical Orthopedic Surgery Atlas", "Tumor TNM Staging Atlas", "Chinese Expert Consensus on the Surgical Treatment of Multiple Myeloma Bone Disease", "Guidelines for the Diagnosis and Treatment of Malignant Melanoma", "Chinese Expert Consensus on the Diagnosis and Treatment of Soft Tissue Sarcomas", etc., and participated in the translation of many oncology monographs. In recent years, the department has made great progress in the treatment of axial bone tumors. The team with Director Wang Guowen as the core, including the anesthesiology department, interventional department, intensive care department, operating room and other departments, has actively cooperated and has independently completed the three most difficult surgeries recognized in the world: posterior total vertebral body surgery. Resection (enblock), pelvic tumor resection mainly for pelvic area II tumors, artificial hemipelvic reconstruction surgery, and total sacrum resection and reconstruction surgery. In addition, we are at the forefront of molecular pathological diagnosis and targeted drug application in the country, and are at the forefront of soft tissue malignant tumor resection. View full introduction

Biological Therapy Department›

The Biotherapy Department of Tianjin Medical University Cancer Hospital was founded in 1972. It is one of the earliest medical units in China to carry out tumor biotherapy. In 2006, the Clinical Application Professional Committee of the China Medical Biotechnology Association was established here, and it is now the clinical research base of the China Medical Biotechnology Association. The Biotherapy Department is divided into two parts: the Biotherapy Department and the Biotechnology Research Laboratory. It is a special department that closely integrates clinical and basic research. The Department of Biotherapy currently has more than 100 beds and 17 general practitioners, including 3 chief physicians (including 1 specially appointed expert), 4 deputy chief physicians, 1 doctoral supervisor, and 3 master supervisors. The treatment methods of the department organically integrate chemotherapy and radiotherapy on the basis of highlighting biological treatment, and gradually form a treatment strategy with its own style. The department continues to innovate in research and applications such as stem cell therapy (autologous and allogeneic), tumor DC vaccine therapy, and adoptive immune cell therapy. In the early 1990s, he presided over the successful transhepatic artery infusion of LAK cells derived from autologous spleen cells to treat liver cancer, and since then he has entered the stage of modern tumor biological therapy research. The blood cell collection instrument - CS-3000 was introduced and a GMP laboratory was established. After acceptance by the Ministry of Health, it was designated as an application unit for autologous LAK cell treatment of solid tumors. It has achieved good therapeutic effects in kidney cancer, melanoma, gastrointestinal tract and liver cancer. In particular, it can significantly improve the quality of life of patients, extend their survival period, and even enable some advanced patients to achieve long-term survival. Following LAK cells, the department has successively carried out adoptive cell immunotherapy projects such as CIK cells, DC+CIK, R-CIK, and NK. The department started research on CIK cell therapy in 2000, established a complete technical system for CIK cell preparation, clinical treatment and immune efficacy testing, and also explored the tumor-suppressing mechanism of CIK cells. In 2006, the CIK cell therapy project was approved by the State Food and Drug Administration (SFDA) to enter clinical trials. It has achieved relatively ideal therapeutic effects in the treatment of lung cancer, kidney cancer and digestive tract tumors and has been used in clinical treatment. For example, a total of 105 lung cancer patients received CIK treatment combined with chemotherapy from 2006 to 2009, and a total of 19 patients were lost to follow-up until March 2010. Among all 96 evaluable lung cancer cases, 26 were early-stage cases, OS ranged from 1 to 79 months, and the median survival time was 48.5 months. Through univariate analysis, it was found that the number of CIK treatments had a significant impact on patients' OS. The median survival time of patients with more than three CIK treatments (20 cases) was significantly longer than that of those with three or less treatments (6 cases). There were 70 advanced cases, OS ranged from 1 to 64 months, and median survival time was 11.5 months. Compared with the median survival time of 7.9 months in 1594 patients with advanced lung cancer treated with conventional chemotherapy regimens reported by ECOG, the median survival time of patients receiving CIK treatment was extended by 3.6 months. The more times CIK treatment is performed, the better the effect. The Department of Biotherapy initiated the establishment of the China Cancer Immunotherapy Collaborative Group, which provides solid evidence-based medical evidence for the clinical application of tumor immunotherapy by designing and conducting multi-center clinical trials in the field of tumor immunotherapy approved or commissioned by relevant administrative departments, and promotes the standardization and healthy and orderly development of the clinical application of tumor immunotherapy in my country. The prospective, randomized, open, multi-center clinical study of autologous cytokine-induced killer cells (CIK) combined with chemotherapy for the treatment of lung squamous cell carcinoma initiated by the Department of Biotherapy was funded by the National Science and Technology Support Program. In addition, the department also carries out autologous inactivated tumor vaccine combined with GM-CSF active immunotherapy. This project uses its own inactivated tumor cells as tumor antigens, combined with GM-CSF as an adjuvant, to prepare tumor vaccines and stimulate specific anti-tumor immune responses in patients. The project has applied for technical approval from the Ministry of Health and passed expert review. We carry out research on new biotherapy technologies such as dendritic cell (DC) vaccines, activated allogeneic hematopoietic stem cell therapy, and NK cell therapy, which have improved the quality of life for tumor patients. We are in a leading position in the country in terms of adoptive immunotherapy and vaccine therapy for malignant solid tumors, and have successively held national biotherapy conferences and biotechnology continuing education training courses. In 2010, the department participated in the "Research on Technical Standards Related to Immunotherapy and Somatic Cell Therapy" organized by the Ministry of Health and conducted clinical application research on DC vaccines. In addition, the department has successively carried out international and domestic multi-center clinical trials of multi-target drugs sunitinib, axitinib, pazopanib and anlotinib for the treatment of advanced renal cancer; He has participated in a number of domestic and foreign clinical trials of CTLA-4 antibodies and PD-1 antibodies, and has accumulated rich experience in tumor immunotherapy and targeted therapy. The department has won honorary titles such as the school-level Worker Pioneer Award and the college-level Youth Civilization Award, and has won the college-level Outstanding Department Award for three consecutive years. In the past five years, it has received more than 20 projects from the National Science and Technology Support Plan, the National Science and Technology Research Plan, the National 973 Special Project, the National 863 Special Project, the National Natural Science Foundation, and Tianjin Municipal Science and Technology Commission key projects. It has published nearly 100 papers included in SCI and obtained 1 patent authorization. It has trained more than 30 master's/doctoral students and international students in total, cultivating and delivering a group of innovative talents to my country's medical field. He is the editor-in-chief of "Cellular Immunotherapy of Solid Tumors" and co-editor of many oncology monographs such as "Abdominal Oncology", "Concise Oncology", "Head and Neck Oncology", and "New Advances in Oncology". The Department of Biotherapy has established close cooperation and exchanges with many well-known foreign research institutions, such as Nippon Takara Bio Co., Ltd. It trains 7-8 doctoral and master's students every year, and many young doctors in the department have experience of studying abroad. View full introduction

Department of Molecular Imaging and Nuclear Medicine›

The Department of Molecular Imaging and Nuclear Medicine Diagnosis and Treatment of Tianjin Medical University Cancer Hospital was officially established in 2009. It was formed by the merger of the PET-CT Center established in 2004 and the Department of Nuclear Medicine (then known as the Isotope Laboratory) established in 1958. Professor Xu Wengui served as the first department director and subject leader. After more than ten years of rapid development, it has gradually become a first-class nuclear medicine professional department in China integrating diagnosis, treatment, scientific research and teaching. At present, the main departments of the hospital mainly include four parts: PET-CT center, SPECT-CT center, nuclide therapy ward and molecular imaging basic laboratory. The Department of Nuclear Medicine of Airport Campus was also officially established in November 2019. The department has a reasonable talent echelon, clear division of labor, full of innovative vitality and strong competitiveness. There are currently 63 staff members, 7 with senior professional titles, 14 with intermediate professional titles, and 42 with junior professional titles, including 19 physicians, including 2 postdoctoral fellows, 9 PhDs (3 are currently studying), and 7 masters. It has made great achievements in teaching and talent training. It has trained nearly 70 doctoral and master's students, and has provided a large number of professional backbones to many places to enrich themselves in the front line of clinical scientific research. The department undertakes 3 National Natural Science Foundation projects, 4 provincial and ministerial-level projects such as the Tianjin Natural Science Foundation, 6 school and bureau-level projects such as the Tianjin Municipal Education Commission, 2 National Clinical Center projects, and many other horizontal projects; Participated in 3 projects of the Ministry of Science and Technology during the “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan”. Undertaken and initiated 5 multi-center clinical studies and participated in more than 10 clinical trials; Won one Tianjin Municipal Science and Technology Progress Third Prize, one Tianjin Medical University Science and Technology Achievement Award, and one Tianjin Municipal Achievement Appraisal Award; He has published more than 90 academic papers, of which nearly 30 are included in SCI, with a cumulative impact factor of more than 70 points, and he has edited or participated in the editing of many academic books. Pioneering and enterprising (2004-2008) In 2004, the hospital introduced positron emission computed tomography (PET-CT), established a PET-CT center, and introduced Professor Xu Wengui from Bethune Medical University as department director and subject leader. When the PET-CT Center was first established, it brought together professionals from various disciplines and hired Professor Bao Runxian as a consultant, representing the top level of the hospital's medical imaging field at that time. Through the unremitting efforts of all members of the general practice, clinicians have gradually become familiar with, recognized and relied on PET-CT from strangers and even doubts. The number of PET-CT examinations has also continued to rise. By 2008, the number of annual PET-CT examinations had reached 1,728, accounting for more than 50% of the city's total. On December 19, 2008, the PET-CT Center and the Institute of High Energy Physics of the Chinese Academy of Sciences jointly built a joint laboratory for molecular imaging that was officially launched. It received project support from the Ministry of Finance to build a platform for cell and animal experiments and the research and development of new molecular probes. After repeated exploration and attempts, basic and preclinical research on the development and imaging of a series of new radioactive drugs, including 18F-FES estrogen receptor imaging, 18F-FLT cell proliferation imaging, 18F-FHBG reporter gene imaging, 11C-PD153035 epidermal growth factor imaging, 11C-acetate imaging, and 18F-choline imaging, have been carried out, and fruitful scientific research results have been achieved. From learning and exploration at the beginning to becoming more familiar with it later, every step in the development of the PET-CT center has been steady and steady. By the end of 2008, the PET-CT center had a total of 7 employees, including 4 doctors (all with postgraduate degrees). Director Xu Wengui led everyone to deeply explore the clinical application of PET-CT in tumor diagnosis and treatment, gradually formed its own characteristics, and began to emerge in the field of tumor molecular imaging across the country. Forge ahead (2009-2020) In 2009, the PET-CT Center merged with the Department of Nuclear Medicine to formally establish the Department of Molecular Imaging and Nuclear Medicine Diagnosis and Treatment. Professor Xu Wengui from the original PET-CT Center was appointed as the department director, forming a more powerful force. Since then, the development of the department has entered a fast lane. After the establishment of the new department, under the leadership of Director Xu Wengui, the inspection process was further sorted out and standardized, a report quality evaluation team was established, business learning and scientific research investment were strengthened, department system construction and discipline construction were strengthened, and efforts were made to build the nuclear medicine brand of Tianjin Medical University Cancer Hospital. In order to meet the growing examination needs of patients, the department comprehensively upgraded the cyclotron (GEMINITRACE) and PET-CT (GEDiscoveryST4 type) in October 2014, and successively purchased PET-CT machines (GEDiscoveryelite type), SPECT (G EDiscoveryinfina), SPECT-CT machine (SIMENS Symbio Intervo16), SPECT-CT machine (GEDiscoveryNM/CT670PRO), and breast-specific PET machine (PEMi), which have significantly shortened the waiting time for appointments and have been well received by patients. Taking both diagnosis and treatment into account is a specialty of nuclear medicine. The department established a nuclide therapy ward on August 9, 2010, which mainly carries out 131 iodine treatment for differentiated thyroid cancer, radioimmunotherapy for liver cancer, radioactive seed implantation therapy, 89SrCl2 treatment for multiple bone metastases, etc. The introduction and development of related technologies have filled many gaps in the Tianjin Medical University Cancer Hospital and even Tianjin City, bringing hope and good news to the majority of cancer patients. On November 18, 2019, the Molecular Imaging and Nuclear Medicine Diagnosis and Treatment Department of Airport Hospital was established relying on the high-quality hardware resources of Tianjin Cancer Hospital Airport Hospital and the policy advantages of the bonded zone. So far, the department (headquarters and airport) has a total of two PET-CT units, three SPECT (including SPECT-CT) units, one cyclotron, and 19 radioactive isolation single rooms. The clinical workload of the department continues to grow. As of the end of 2020, the annual PET-CT examination volume has increased from the initial 500 to nearly 9,000, the annual SPECT examination volume has increased from 3,409 before the merger of the department in 2008 to 9,620, and the nuclide ward has admitted nearly 1,000 patients annually. The department strengthens external exchanges and learning, adheres to the combination of "going out" and "inviting in", and has successively sent business backbones to Nanfang Hospital, University Hospital of Zurich in Switzerland, South Korea Atomic Energy Hospital, and MD Anderson Cancer Center in the United States for exchanges and studies. It has also hired many well-known experts as visiting professors and cooperative professors, which has improved the department's business and scientific research levels and broadened its horizons. After more than ten years of hard work, the Department of Molecular Imaging and Nuclear Medicine Diagnosis and Treatment has always followed the forefront of world imaging and nuclear medicine with a spirit of pioneering and innovation, and has continued to grow and develop. As of the end of 2020, the department has a total of 63 employees, including 2 postdoctoral fellows, 9 PhDs (3 are currently studying), 20 masters, 7 with senior professional titles, and 14 with intermediate professional titles. Among them, Professor Xu Wengui, director of the department, won the Third Doctors’ Day Excellence Award and was named the first “Tianjin Famous Doctor” by the Tianjin Municipal Health Commission in 2020. Li Xiaofeng won the title of 131 Innovative Talents in Tianjin Universities in 2017; Li Xiaofeng and Yu Xiaozhou were awarded the title of Outstanding Young Innovative Talents of the hospital. As a standardized training base for resident doctors in Tianjin, the department recruits regular trainees and advanced students all year round, and is committed to training doctoral and master's degree students. It has trained nearly 70 graduate students in total, constantly accumulating energy for the future development of nuclear oncology medicine in my country. In addition, the department has trained young doctors through graduate student meetings, departmental academic lectures, and reading competitions, and has achieved fruitful results. Many of them have won awards in multiple domestic PET/CT reading competitions, demonstrating the technical level and elegance of nuclear medicine in Tianjin Medical University Cancer Hospital, and winning recognition and praise from their peers. In terms of basic scientific research, the department undertakes 3 National Natural Science Foundation projects, 5 provincial and ministerial-level projects such as the Tianjin Natural Science Foundation, 10 school and bureau-level projects such as the Tianjin Municipal Education Commission, 2 National Clinical Center projects, and many other hospital-level and horizontal projects; Participated in 3 projects of the Ministry of Science and Technology, including the “12th Five-Year Plan” and the “13th Five-Year Plan”, and won one third-class Tianjin Science and Technology Progress Award, one Tianjin Medical University Science and Technology Achievement Award, one Tianjin Achievement Appraisal, and published more than 90 academic papers, of which nearly 30 were included in SCI, with a cumulative impact factor of more than 70 points. On December 18, 2015, Professor Xu Wengui took the lead in establishing the Nuclear Oncology Committee of the Chinese Anti-Cancer Association and was elected as the first chairman. Tianjin Medical University Cancer Hospital also became the first national committee unit in the field of nuclear medicine in Tianjin. Many people in the department have successively served as directors, youth directors, committee chairmen, committee members and youth committee members of the Chinese Anti-Cancer Association. They have taken the lead in organizing multiple national multi-center clinical studies and the formulation of PET-CT diagnosis and treatment standards. They have undertaken a large amount of organizational work and more social responsibilities, and their disciplinary status in the country has been further enhanced. The Department of Molecular Imaging and Nuclear Medicine Diagnosis and Treatment has always been a mainstay and has a sense of responsibility as a leader in the industry. It has never stopped making breakthroughs and innovations, striving to contribute to the cause of cancer prevention and treatment in my country. View full introduction

Breast Pathology Laboratory›

The Breast Pathology Laboratory of Tianjin Medical University Cancer Hospital was established in 1985. It is currently the only first-level clinical department at home and abroad that specializes in pathological diagnosis and research of breast diseases. It is the initiator of the National Breast Cancer Pathology Collaboration Group and a national key clinical specialty. It is the only Chinese female breast cancer prevention and control research innovation team of the Ministry of Education, an important component and academic leader and team leader of the 863 major project team of the Ministry of Science and Technology. It is an important component of the National 211 Project Key Disciplines in Colleges and Universities, the National (Ministry of Education) Key Laboratory, and the Tianjin Key Laboratory. After 36 years of hard work and innovative development, on the basis of standardized, individualized and precise clinical pathological diagnosis, the department has developed technologies such as chemotherapy drug sensitivity testing in primary tumor cell culture that simulates the human body environment, one-step nucleic acid method sentinel lymph node rapid detection, PIK3CA mutation detection, ATP chemiluminescence chemotherapy drug sensitivity testing and other technologies, providing a strong guarantee for the accurate diagnosis and treatment of breast cancer. The department has the largest external examination volume for breast pathology diagnosis at home and abroad, the only full information database of breast cancer surgery patients, and has been included in the National Population Health Science Data Sharing Platform. It has undertaken more than 70 scientific research projects including the National 863 Major, 973 Major, 863 Support, National Natural Science Foundation Key, General, and Youth Projects, received more than 40 million yuan in scientific research funding, and published more than 400 scientific research papers in domestic and foreign academic journals such as Nature Communications. She has won more than 20 awards, including three provincial and ministerial first prizes, the China Association for Science and Technology’s First National Excellence Award, the Ho Leung Ho Lee Award, the Wuzhou Women’s Science and Technology Progress Award, and the China Federation of Returned Overseas Chinese Innovative Talent Award. There are currently 22 pathological diagnosticians, including 9 with senior professional titles, 3 doctoral supervisors, and 6 master's supervisors; One academician of the Royal College of Pathologists, one expert from the State Council, and one expert from the Ministry of Health; 1 Tianjin Distinguished Professor, 2 Tianjin Famous Doctors, and 1 Tianjin “131 Innovative” second-level talent; 7 people have overseas study experience, and 10 people have postdoctoral training experience. The Breast Pathology Laboratory is a standardized training base for doctors of the National Health Commission. Every year, it accepts clinical internship teaching and teaching work from many universities and colleges, including pathologists, senior visiting scholars, and advanced students from home and abroad. It has trained a total of 8 postdoctoral fellows, and more than 400 doctoral and master's students, foreign students, and advanced students. It has hosted more than 20 large-scale international academic conferences and various training courses such as the International Symposium on Pathology and Clinical Symposium on Individualized Diagnosis and Treatment of Breast Cancer, and has conducted extensive academic exchanges with internationally renowned professional medical research institutions in Japan, the United States, the United Kingdom, the Netherlands, Germany, and Italy, and has established good scientific research partnerships. He is the editor-in-chief of more than 20 monographs on breast pathological diagnosis, including "Standards for Pathological Examination of Breast Cancer", "Breast Tumors Volume of Chinese Pathological Classification of Tumors", "Diagnostic Atlas of Breast Tumor Pathology", "Color Atlas of Breast Diseases", "Self-Discovery of Breast Cancer", "Diagnostic Atlas of Breast Cytology", "Diagnostic Pathology of Breast Tumors", "Pathology of Breast Tumors", "Color Atlas of Pathological Pathology of Breast Diseases" second edition, and participated in the compilation of the fourth and fifth editions of "World Health Organization Classification of Breast Tumors". In line with the purpose of "accurate pathological diagnosis and everything centered on the patient", the department conducts quality control throughout the entire process from specimen reception, fixation, extraction, slicing, staining to report issuance to ensure the quality, safety and accuracy of pathological diagnosis. We always adhere to the focus on medical quality, guide and assist clinicians in the diagnosis, treatment and prognosis of patients' diseases, and provide satisfactory services to clinicians and patients. View full introduction

Pancreatic Tumor Department›

The Pancreatic Oncology Department of Tianjin Medical University Cancer Hospital was established in 2008 and is the earliest pancreatic oncology department established in China. After more than ten years of development under the leadership of Professor Hao Jihui, it has become one of the leading units in the clinical diagnosis, treatment and translational research of pancreatic tumors in China. In 2016, it was successfully selected as a key discipline of the National Cancer Clinical Research Center. As the largest pancreatic tumor diagnosis and treatment center in the north, it currently has 60 beds and 12 doctors, including 2 chief physicians, 5 deputy chief physicians, and 5 attending and resident physicians; There is one doctoral supervisor and five master's supervisors. Many doctors have studied abroad or trained in famous universities in the United States, Japan, Sweden, etc. The diagnosis and treatment scope of the center includes comprehensive treatment of benign and malignant tumors of the pancreas, duodenum, biliary tract and retroperitoneum with surgery as the core. In recent years, the center has continuously improved the level of medical diagnosis and treatment, and has promoted a series of new technologies: pancreaticoduodenectomy with standard/extended lymph node dissection for malignant tumors in the ampulla, low bile duct, and pancreatic head; pancreatoduodenectomy with artery-first approach for malignant tumors in the uncinate process; and RAMPS surgery for pancreatic body and tail cancer, which has greatly increased the rate of tumor R0 resection and delayed the disease-free survival time of patients. In addition, minimally invasive pancreatic surgery has successively carried out laparoscopic and da Vinci robotic pancreatoduodenectomy, spleen-preserving pancreatic body and tail resection of benign pancreatic tumors, which has greatly alleviated the pain of patients and shortened the hospitalization time; The center explores and carries out comprehensive treatment of localized tumor radiotherapy combined with chemotherapy for patients with locally advanced pancreatic cancer; The center is also at the leading domestic and world-class level in the diagnosis and treatment of pancreatic neuroendocrine tumors; The center hosts and participates in a number of clinical trials and studies to provide pancreatic cancer patients with internationally synchronized diagnosis and treatment methods. The Department of Pancreatic Oncology diagnoses and treats more than 30,000 patients annually, and completes more than 600 pancreatic surgeries of various types annually on average, forming the disciplinary characteristics of “individualized comprehensive treatment of pancreatic tumors with surgical treatment as the core”. Relying on the National Cancer Clinical Research Center, the team has carried out a series of original basic translational research on pancreatic cancer, which has greatly improved the diagnosis and treatment of the disease and extended the survival time of patients. The basic and clinical research on refined diagnosis and treatment of pancreatic cancer has won the first prize of Tianjin Science and Technology Progress Award and the first prize of China Anti-Cancer Association Science and Technology Award. Scientific research and innovation achievements Team members have received a total of 56 research funds at the provincial or ministerial level, including 45 National Natural Science Foundation key projects, outstanding youth funds, major international cooperation projects, general projects, and youth funds; Obtained 22 innovative talent support plans at all levels, These include the Yangtze River Scholars Distinguished Professor of the Ministry of Education, the Ten Thousand Talents Program Leading Talents, the National Hundreds and Thousands Talents, the Tianjin Distinguished Professor, and the Tianjin 131 Innovative Talents; Selected into the Ministry of Science and Technology’s “Digestive Tract Tumor Diagnosis and Treatment” Innovation Team, Tianjin 131 Talent Innovation Team and other titles. The center has various research funds of more than 20 million yuan and has published more than 100 SCI papers in authoritative academic journals on oncology such as Gastroenterology, Nature Communications, Advanced Functional Materials, and Cancer Research. Established the "Tianjin Model" for early diagnosis of pancreatic cancer, proposed chemoprevention strategies for pancreatic cancer, and improved the cure rate of pancreatic cancer. As the main person in charge, he participated in the formulation of the "China Pancreatic Tumor Diagnosis and Treatment Guidelines" and has important academic influence in the same field at home and abroad. View full introduction

Pharmacy Department›

The Department of Pharmacy of Tianjin Medical University Cancer Hospital is a hospital pharmacy department integrating pharmaceutical services, pharmaceutical management, teaching and research. Currently, the Department of Pharmacy is the clinical pharmacist training base of the National Health Commission and Tianjin Municipal Health Commission, the deputy director unit of Tianjin Quality Control Center, the Tianjin intravenous drug dispensing standardized operation demonstration unit, and the training site and internship base for master's students in the School of Pharmacy of Tianjin Medical University. At the same time, research work on pharmaceutics, clinical pharmacy, clinical pharmacokinetics, pharmaceutical information and computer applications is closely integrated with clinical practice. The Department of Pharmacy has 8 sub-departments, including Chinese and Western medicine warehouse, outpatient pharmacy, herbal medicine pharmacy, inpatient pharmacy, daytime intravenous drug dispensing center, inpatient intravenous drug dispensing center, clinical pharmacy department and quality control research department. The department has a total of 82 professionals, including 3 with senior professional titles, 5 with deputy senior professional titles, 1 lecturer, and 39 pharmacists in charge; There is 1 postdoctoral fellow, 4 PhDs, and 29 masters. The Department of Pharmacy manages nearly 1,000 types of anti-tumor drugs and related therapeutic drugs throughout the hospital, including more than 700 varieties and specifications of Western medicines, nearly 100 kinds of Chinese patent medicines, and nearly 200 kinds of Chinese medicine granules. Strictly implement national regulations and adjust prices in a timely manner. Pay attention to improve drug quality management in routine work, work through multiple channels such as procurement acceptance, shelf inspection, clinical feedback, etc. and make timely improvements. Drug information is required to be supported by scientific research and literature research evidence, and the quality of the hospital and externally processed preparations is regularly inspected to provide clinical and patients with assured drugs. As a permanent institution of the hospital's Pharmacy Committee, the Pharmacy Department handles various problems encountered in the use and management of drugs in a scientific and rigorous manner, and gradually improves relevant systems. Department features: (1) Management of narcotic drugs and psychotropic drugs Since the WHO's three-step cancer analgesia principle was introduced into my country, after long-term practice and exploration, a complete set of management methods for narcotic drugs and psychotropic drugs has become a unique and widely promoted advanced model in Tianjin. On the premise of relieving patients from pain problems, standardized management of narcotic drugs is achieved. (2) Automation of drug dispensing With the introduction of advanced equipment such as automatic medication dispensing machines, automatic medication dispensing machines, intelligent management cabinets for narcotic drugs and valuable drugs, traditional Chinese medicine granulators, and intelligent medication dispensing and sorting systems (PDA), the automation of drug dispensing has been realized. While comprehensively improving work efficiency, medication safety is ensured. In addition, the herbal medicine dispensary also launched the mailing service of SF Express granules to facilitate out-of-town patients to obtain medicines and save waiting time. (3) Internet pharmaceutical services The opening of the Internet hospital allows patients to enjoy the service of online drug purchase and home delivery. The pharmacy service platform of Tianjin Cancer Hospital was officially launched on January 27, 2021. It covers medication scanning, medication consultation, medication testing, medication reminders, medication records, adverse reaction reporting, pharmaceutical science articles and many other contents, providing guarantee for patient safety and rational medication use. (4) Centralized allocation of intravenous fluids The intravenous liquid dispensing center is responsible for the dispensing of anti-tumor drugs and parenteral nutrition (TPN) in the hospital. It has the characteristics of small and precise layout and smooth operation order. The dispensing process of "four-on-one reminders after first review" of drugs ensures the quality of drug dispensing. The daytime intravenous drug dispensing center on the 8th floor of the outpatient clinic is the first in the city. Through the optimization of the process, it has reduced the turnover of patients and improved the service level. (5) Outpatient drug consultation In 2020, the Drug Consultation Center set up an independent clinic on the 6th floor of the outpatient clinic and equipped it with corresponding diagnostic equipment. Patients can register through online appointments and on-site operations. The consultation content mainly focuses on anti-tumor drugs, radiation pain drugs, anti-infective drugs, nutritional drugs, pediatric-related therapeutic drugs, anticoagulant drugs, etc. (6) Organize and provide drug information Pharmacists participate in the collection and organization of clinical data such as clinical ward rounds, medical record review, and summary of clinical medication experience, and summarize and analyze the organized content, and then feedback the analysis results to the clinic to provide a reference for the rational use of clinical drugs. Assist the hospital pharmaceutical committee in the preliminary screening, comparison and sorting of new drugs. Provide clinical information on drug action mechanisms, clinical application indications, medication methods, precautions, adverse reactions and other information in a timely manner. (7) Edit "Pharmaceutical Newsletter" "Pharmaceutical Newsletter" is issued every quarter. The content focuses on highlighting the characteristics of oncology specialty, promptly introducing rational drug use information, new drug introduction, drug usage status, etc. to the clinic, strengthening the connection with the clinic, and promoting safer and more reasonable clinical drug use. In addition, the hospital's "Doctor's Medication Manual", "Basic Medication List", and "Compilation of Drug Instructions" are regularly compiled and updated. (8) Monitoring of adverse drug reactions Carry out adverse drug reaction monitoring and reporting work, and implement an online reporting system since 2003. The hospital monitoring team mainly collects and organizes adverse reactions caused by clinical use of drugs, monitors the safe use of drugs, and reports the information to the National Adverse Drug Reaction Monitoring Center. At the same time, adverse reactions are collected, sorted and analyzed, and possible adverse reactions of drugs are fed back to clinicians to facilitate rational clinical use of drugs. (9) Clinical pharmacy practice and services The Department of Pharmacy established the Clinical Pharmacy Office in 1994. Through continuous exploration and development, a relatively mature and complete clinical pharmacist system and clinical pharmacist team have gradually been formed. In the long-term clinical pharmacy service work, the clinical pharmacist team has developed steadily by adhering to the tenets of unity, diligence, pragmatism and innovation, constantly accumulating basic medical knowledge, enriching clinical experience, and using pharmaceutical professional knowledge to serve the clinic and serve patients. In 2006, it was awarded the first batch of national Ministry of Health clinical pharmacist training base qualifications. Currently, it has three teaching majors: oncology, critical illness and pain, and has trained more than 90 clinical pharmacists nationwide. The department currently has 10 full-time clinical pharmacists in 7 majors, including oncology, infection, nutrition, pain, ICU, pediatrics, and anticoagulation, all with master's degrees or above. Clinical pharmacy services cover the entire hospital, with prominent pharmaceutical work priorities, both medical and surgical care, and distinctive features. Pharmacists, together with their clinical departments, doctors, and nurses form a treatment team to provide professional pharmaceutical support to medical staff and ensure safe, economical, and effective medication for patients. Currently, clinical pharmacy is responsible for prescription reviews, doctor order review, and special evaluation of rational use of drugs in hospital pharmacy management. It also conducts special reviews of anti-tumor drugs, antibacterial drugs, proton pump inhibitors and other key drugs and reviews the use of outsourced drugs to comprehensively improve the rationality of drug use. Participated in many network monitoring tasks such as the International Network for Rational Use of Drugs (INRUD) China Central Group Prescription Review Monitoring Network, the National Adverse Reaction Monitoring Network, and the Ministry of Health Antimicrobial Drug Monitoring Network. (10) Clinical pharmaceutical research Equipped with high-performance liquid chromatography (HPLC), visible ultraviolet spectrophotometer, high-speed centrifuge, electronic analytical balance, etc., it cooperates with clinical departments to measure drug stability, blood drug concentration, etc. Talent training, scientific research and teaching The Department of Pharmacy attaches great importance to the cultivation of pharmaceutical talents, and the scale of clinical pharmacists and teaching staff is constantly expanding. Meng Shuai completed his postdoctoral research at Moffitt Cancer Research Center. Many pharmacists have completed standardized training for clinical pharmacists at training bases such as China-Japan Friendship Hospital and Peking University People's Hospital. Two clinical pharmacists have participated in the American MTM pharmacist qualification training program. Form a team of oncology clinical pharmacists with a focus on anti-tumor expertise and joint development of multiple specialties. Increase the training of pharmacists who review prescriptions, significantly increase their ability to review prescriptions, and lay the foundation for the comprehensive launch of systems related to rational drug use. In 2016, Du Xiaolang won the first place in Tianjin's "Job Training and Technical Competition" pharmacy skills competition. From 2018 to 2020, clinical pharmacists won the first prize in the Beijing competition area and the second prize in the Tianjin competition area in the National Oncology Pharmacy Service Case Competition. The lung oncology medical treatment team in which clinical pharmacists participated won the first place in the national vomiting-free ward competition. As of 2020, the Department of Pharmacy currently has 10 full-time clinical pharmacists, 7 of whom have obtained teaching qualifications. Nearly 90 clinical pharmacy students from more than ten provinces, municipalities and autonomous regions across the country have been trained through projects such as the Chinese Hospital Association and the "Shortage Talent Plan". Since 1997, he has been responsible for the internship work of undergraduate graduates of the School of Pharmacy of the Medical University. He has taught nearly 300 people so far, and more than 30 undergraduates have completed their graduation thesis under the guidance of department staff. Taught more than 50 students from technical secondary schools and vocational schools. In 2014, our department became the master's training center of Tianjin Medical University and trained 3 master's degree graduates. With the introduction of pharmaceutical talents and the increase in external exchanges, related scientific research and teaching have also experienced long-term development. Wu Chunnuan and Zhang Xiaolong respectively chaired one National Natural Science Foundation of China project. Since 2015, department staff have undertaken more than 20 scientific research projects, with scientific research funding of more than one million yuan, including 2 national-level projects, 2 provincial-ministerial-level projects, 7 bureau-level projects, and 3 college-level projects. Published more than 70 papers, including 5 SCI papers and 93 core papers. Under the guidance of the national medical system reform, the Department of Pharmacy is gradually developing towards precision and refinement, aiming to provide patients with comprehensive, full-chain pharmaceutical services and achieve rational, safe and effective medication use. View full introduction

Pediatric Oncology›

The Department of Pediatric Oncology of Tianjin Medical University Cancer Hospital was founded in 1982. It was personally initiated and established by Professor Jin Xianzhai, the founder of oncology in my country, based on the characteristics of children's tumors. It implements a diagnosis and treatment model that integrates internal medicine, surgery, radiotherapy and other methods. It is a professional diagnosis and treatment base for children's tumors in my country. It now has a large-scale, multi-disciplinary team of pediatric oncology professionals, including internal medicine, surgery, radiotherapy, radiology, pathology, anesthesiology and child care professionals. There are 35 pediatric clinical medical staff, including 11 physicians, 1 scientific research assistant, 5 technical staff with associate senior professional titles or above, 4 with doctorate degrees, and 5 with master's degrees. The children's tumor team also includes: 4 pediatric anesthesiologists from the Department of Anesthesiology, 3 from the pediatric tumor radiation therapy professional group from the Radiotherapy Department, 3 from the pediatric tumor pathology sub-professional group from the Pathology Department, and 2 from the pediatric tumor radiation imaging professional group from the Radiation Imaging Department. There are currently 38 hospital beds, and outpatient day ward treatment is also carried out, mainly treating children and adolescents under the age of 18 with various benign and malignant tumors. The annual outpatient visits are more than 9,000, the hospital treats about 2,000 children, and performs more than 300 operations. Malignant tumors in children treated mainly include: lymphoma; Neuroblastoma, rhabdomyosarcoma, hepatoblastoma, nephroblastoma, pancreatoblastoma, osteosarcoma, Ewing's sarcoma, primitive neuroectodermal tumor, malignant peripheral nerve sheath tumor, etc.; Benign tumors mainly include: hemangioma, lymphangioma, various benign tumors of bone and soft tissue, etc. The Department of Pediatric Oncology can provide full-process management and one-stop service for children with cancer, and insists on providing a standardized diagnosis and treatment model that combines multiple disciplines such as tumor molecular diagnosis, surgery, internal medicine, radiotherapy, and immunotherapy, so that children with cancer can receive reasonable and standardized diagnosis and treatment. The department adheres to the multidisciplinary team consultation and cooperation system for children's oncology to formulate the best individualized treatment plan for children, so that children can receive accurate diagnosis and provide guarantee for their treatment and prognosis stratification, so as to achieve the expected curative effect. Through neoadjuvant chemotherapy, tumors that cannot be removed by primary surgery can be completely resected. The department has carried out clinical trials of new drugs in recent years to provide survival opportunities for children with relapsed and refractory malignant tumors. Among them, the radiotherapy team led by deputy chief physician Wang Peiguo of the Department of Radiotherapy can combine it with chemotherapy in a timely manner and use radiotherapy technologies such as conformal intensity modulated radiotherapy, radiofrequency ablation, and cyberknife to significantly improve the cure and survival rates of children with malignant tumors such as rhabdomyosarcoma, neuroblastoma, and Wilms tumor. The sub-professional group of children's tumor pathology department led by Director Cao Wenfeng is in line with international standards, combining cell morphology/cytochemistry, molecular genetics, molecular biology and other technologies, and its treatment level is in a leading position in the country. The Department of Pediatric Oncology is the chairman unit of the Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association. It attracts a large number of patients every year, and the proportion of patients from other places is as high as 75%. It leads the work of the National Neuroblastoma Collaborative Group and is the chairman unit of the Pediatric Oncology Professional Committee of the Tianjin Anti-Cancer Association. It has established and maintained extensive exchanges and collaborations with many medical research institutions at home and abroad. It dynamically pays attention to the new progress in basic research and clinical diagnosis and treatment of children's tumors at home and abroad, timely introduces and carries out new and effective treatment methods and methods at home and abroad, continuously improves the level of comprehensive treatment based on surgery, and constantly updates treatment concepts. In recent years, the Department of Pediatrics has taken the lead in China in using sequential autologous stem cell transplantation to treat high-risk, refractory and relapsed childhood malignant solid tumors. It has also established procedures related to stem cell collection and high-dose chemotherapy with the support of autologous stem cells, and has incorporated sequential autologous stem cell transplantation into the standardized treatment of high-risk neuroblastoma. In recent years, it has cooperated with the University Hospital of Hong Kong to provide support and help for children with high-risk neuroblastoma to receive GD2 monoclonal antibody treatment after stem cell transplantation. The department also focuses on exchanges and cooperation with foreign countries, and signed a strategic cooperation memorandum with the German Cancer Research Center to improve the level of domestic pediatric tumor genomics research. Through exchanges and cooperation at home and abroad, it has achieved great breakthroughs in scientific research. It has become the first domestically approved unit to be funded by the National Ministry of Science and Technology’s key R&D program, and has conducted in-depth basic and clinical research on high-risk neuroblastoma, with a funding of approximately 12.99 million yuan. Paying attention to teaching and training, it trains master's and doctoral students on average every year, and has trained more than 20 high-level talents. View full introduction

Clinical Laboratory Department›

The Laboratory Department of Tianjin Medical University Cancer Hospital was founded at the beginning of the hospital. After several generations of efforts, it has now become a large-scale medical laboratory center in a tertiary-level hospital that integrates medicine, teaching, research and prevention, and features auxiliary dynamic monitoring of tumor diagnosis and treatment. The laboratory department is currently located on the 5th floor of the new outpatient building (Building D), with a construction area of ​​4000m2. It is composed of seven sub-professional groups: clinical biochemistry group, clinical immunology group, clinical testing group, clinical microbiology group, clinical trial group, special testing group, and specimen management group. The department is equipped with more than 200 sets of internationally advanced large and medium-sized testing equipment of various types, and has carried out more than 400 diagnostic projects. The department continues to introduce new technologies, steadily promotes new projects, and has established a comprehensive clinical medical testing quality management system. With a high-quality professional technical team and optimized work processes, it has formed a unique medical testing platform system for oncology that covers the entire process from early screening, laboratory-assisted diagnosis to clinical treatment monitoring and disease evaluation. With superb technology, accurate reports, and sincere service, more than 6 million inspection reports are sent to clinical sites safely, high quality and quickly every year. The laboratory department is an ISO15189 medical quality and capability accredited laboratory (institution registration number: CNASMT0157), the director unit of Tianjin Clinical Laboratory Quality Control Center, and a key clinical specialty unit of laboratory medicine of Tianjin Medical University. All the staff in the department worked together, and their work was recognized by various departments, and they were awarded the honorary titles of "Tianjin Faculty Pioneer Collective" and "Tianjin Integrity Department"; The Party Branch of the Laboratory Department was awarded the "Pioneer Post of Party Member of Tianjin Medical University Cancer Hospital", "Red Flag Party Organization of Tianjin Medical University", "Advanced Grassroots Party Organization of Tianjin Medical University", and "Vitality League Branch of Tianjin Medical University"; For many years in a row, it has been the winner of the Tianjin Health System’s “Job Training Technology Competition” and the “Tianjin Medical University Cancer Hospital Five-Star Window Quality Service Group”; Won the "Outstanding Contribution Award of Tianjin Institute of Inspection" and the "Outstanding Organization Award of Tianjin Institute of Inspection" and many other titles. With an advanced technology platform, we also focus on building an excellent talent echelon. On the basis of completing clinical work, we actively carry out a series of clinical and scientific research. As the testing center for phase I to IV clinical trials of new cancer drugs at the National Pharmacology Base, we have also undertaken 2 major projects (sub-topics) of the national "863" program in the past five years, hosted 11 National Natural Science (Youth) Fund projects, presided over more than 10 provincial, ministerial and bureau-level projects, and presided over more than 20 college-level projects. In the past five years, he has published more than 40 SCI articles, the highest single SCI article IF>10, more than 20 Chinese-level monographs, more than 40 core medical journals, and is the chief editor, deputy editor, and co-editor of 7 monographs. Currently, among the 60 people in the department, there are 2 chief technicians, 1 chief physician, 10 deputy chief technicians, 2 attending physicians, 17 chief technicians, 2 physicians, and 26 technicians, 55% of whom have a master's degree or above. The Laboratory Department is the clinical teaching and research section of the Laboratory School of Tianjin Medical University and a standardized training base for laboratory physicians of the National Health Commission. It accepts clinical internship teaching and teaching work in the inspection (college) departments of many universities and colleges every year. It currently has 1 doctoral supervisor and 2 master's supervisors, recruits more than 30 doctoral and master's students, and accepts professional training for inspection personnel from all over the country. The department has established talent exchange bases with many internationally renowned medical research institutions, which has laid a solid foundation for the department to send key technical talents to study at advanced diagnostic platforms abroad as postdoctoral fellows and visiting scholars. At present, there are more than 30 technical personnel who have gone abroad for postdoctoral study and training experience. All functional groups in the Laboratory Department work without holidays and insist on starting work at 7:00 a.m. throughout the year to provide patients with safe, high-quality and fast diagnostic services: full-process tracking of samples, timely prompts for abnormal specimens, intelligent summary of real-time data, immediate self-service access to outpatient reports, and historical testing data and trend charts for doctors to query at any time. All staff in the department will continue to strengthen communication and exchanges with clinical departments, strive to explore new models of laboratory medicine, and actively promote the intersection and integration of related majors within and outside the discipline. We will adhere to the quality policy of "realism, innovation, quality, and efficiency", insist on quality improvement, serve patients, and contribute to society. Our service hotline is: 022-23340123. You are welcome to log in to our website and look forward to your guidance on our work. View full introduction

Cerebrovascular Tumor Department›

The Department of Brain Oncology of the Tianjin Medical University Cancer Hospital was established in 1999. It specializes in the diagnosis and treatment of malignant brain tumors, and has unique insights in the fields of surgical treatment, radiotherapy, and interventional therapy for critically ill patients with brain tumors. The department adheres to the concept of "win-win cooperation and innovative development". After 20 years of hard work and hard work, it has continuously achieved new breakthroughs in the surgical treatment of difficult nervous system tumors, and gradually formed a professional brain tumor treatment team based on microsurgery with sub-specialties such as endoscopic surgery, radiosurgery, children's tumors, spinal cord tumors, malignant tumors and chemotherapy targeted comprehensive treatments. The department has 44 open beds and has an independent intelligent neurosurgery specialist operating room. It has an independent laboratory and has cooperated with the Tianjin Cancer Institute to build the "Brain Tumor Precision Treatment Center", making full use of superior resources to actively carry out clinical trials and exploration of translational medicine, and achieved certain results. Currently undertaking 1 national key oncology sub-project and 2 National Natural Fund projects; 5 articles are included in SCI every year, with the highest impact factor of a single article reaching 14 points; Participated in the compilation of 4 monographs related to nervous system tumors. It has attracted neurosurgeons from all over the country to come to our hospital for further study, focusing on cultivating clinical and scientific research talents with international vision and innovative ability, and promoting the collaborative innovation and development of neuro-oncology surgery. The nursing team of the department takes professional leadership as its direction and scientific research and innovation as its development. With the development of minimally invasive technology, the department took the lead in carrying out rapid recovery care, and routine surgeries ensured that patients were discharged from the hospital 5-7 days after surgery. Postoperative patients have made great progress in physical rehabilitation and psychological rehabilitation. View full introduction

Pain Treatment Department›

The Pain Treatment Department of Tianjin Medical University Cancer Hospital is a department specializing in the diagnosis, treatment and management of cancer pain. Its predecessor, the "Pain Relief Clinic", was opened in 1994 and was the first in China to carry out an at-home treatment model for cancer pain patients. In 1996, the hospital jointly participated in the pain relief clinic work with the Department of Integrated Traditional Chinese and Western Medicine and the Department of Oncology, forming a multidisciplinary cancer pain treatment model and leading the country in standardizing cancer pain drug management and treatment. In 2008, with the establishment of the inpatient ward, the development of the pain treatment science department entered the "fast track". Currently, the Pain Treatment Department is one of the first batch of "Cancer Pain Standardized Treatment (GPM) Demonstration Wards" of the National Health and Family Planning Commission, the "CPAI Pain Management Institute Clinical Education Base" of the Chinese Anti-Cancer Association, and the "National Standardized Tumor Nutritional Therapy Demonstration Ward" of the Chinese Anti-Cancer Association. He has trained cancer pain specialists for many oncology hospitals and large general hospitals across the country, and most of them have become academic leaders in cancer pain treatment in their regions. After more than 20 years of development, the department has formed a multidisciplinary treatment model with "palliative care as the main line, cancer pain treatment as the focus, and nutrition and psychological support as the characteristics", which involves drug treatment, minimally invasive interventional treatment, nutritional assessment and intervention, psychological assessment and intervention, and treatment of accompanying symptoms of patients with intermediate and advanced cancer pain. At present, the minimally invasive interventional techniques carried out by the department mainly include nerve damage surgery, radiofrequency thermocoagulation, particle implantation, and percutaneous vertebroplasty, covering various post-tumor pain syndromes, bone metastasis pain, upper abdominal pain caused by retroperitoneal metastasis such as pancreatic cancer and gastric cancer, perineal pain caused by pelvic tumors, and other diseases. In 2017, the number of outpatient visits reached more than 11,950, and the number of inpatients reached more than 480. While completing a large amount of clinical work, the department also actively participates in scientific research and training of cancer pain specialists. Now it has undertaken 1 National Natural Science Foundation of China project and 5 college-level projects. In the past three years, it has published more than 30 papers, including 8 papers included in SCI; Trained more than 30 cancer pain specialists. View full introduction

Ultrasound Diagnostic Department›

The Ultrasound Diagnostic Department of Tianjin Medical University Cancer Hospital was founded in 1980 to focus on ultrasonic diagnosis and ultrasound-guided interventional treatment of tumor patients. After decades of development, the Department of Ultrasound Diagnosis has developed into a comprehensive discipline with sophisticated instruments and equipment, strong technical force, exquisite diagnostic skills, and coordinated development of academic and scientific research transformation. As of the end of 2021, there are currently 35 general medical staff, including 30 doctors (nearly 90% have doctoral and master's degrees, including 3 with senior professional titles and 5 with deputy senior professional titles) and 5 nurses; It has 15 outpatient ultrasound clinics, 9 inpatient ultrasound clinics, 1 special-needs expert ultrasound clinic, and 3 interventional operating rooms. It receives approximately 240,000 patients annually and performs more than 15,000 puncture and interventional treatments, providing reliable clinical diagnostic basis. In addition to routine examinations of the abdomen, pelvis, urology, head and neck, breast and other parts of the body, as the first ultrasound diagnosis and treatment department in Tianjin to carry out interventional ultrasound technology (including ultrasound-guided puncture, thermal ablation therapy, chemical ablation therapy, particle implantation, thoracoabdominal tube drainage, PTCD, etc.), it has attracted a large number of patients both inside and outside the hospital and has been integrated into the regional tumor diagnosis and treatment center. The Department of Ultrasound Diagnosis keeps up with domestic and foreign research trends, uses superficial organ tumors as a breakthrough, and develops new diagnosis and treatment technologies, including AI-assisted diagnosis, ultrasound contrast, elastography, three-dimensional imaging, image fusion imaging navigation technology, SMI technology, etc. It has established a complete and standardized diagnosis process, formed a superior discipline, and has been promoted and applied in many medical centers. The department strives to gradually advance the transformation direction of scientific research, and its achievements have won the Tianjin Science and Technology Progress Award and the China Anti-Cancer Association Science and Technology Award. In terms of teaching, the department is responsible for the training of undergraduates and postgraduates of Tianjin Medical University. It is also the first standardized training base for resident doctors in Tianjin. It also accepts domestic clinical and imaging doctors for further study. It trains 4-6 postgraduates every year and trains more than ten doctors with standardized training. At the same time, it actively participates in academic exchanges and promotions, and has held many Tianjin Head and Neck Imaging Ultrasound Diagnostic Study Classes, National Oncology Study Classes, and National Ultrasound and Oncology Academic Conferences for academic exchanges, and occasionally sends young doctors to hospitals with leading professional and technical levels at home and abroad for further study. In terms of scientific research, as of the end of 2021, more than 130 academic papers have been published, including more than 60 SCI papers. The first artificial intelligence diagnosis article on benign and malignant thyroid nodules was published in the journal "Lancet. Oncology" and has been unanimously recognized by domestic and foreign scholars. He has presided over more than 10 National Natural Science Foundation, municipal bureau-level projects and major special projects. He has won the second prize for innovative new technology achievements of the Medical University twice. He has compiled the "Ultrasound Diagnosis and Pathology Comparison Atlas of Superficial Soft Tissue Diseases" and "Ultrasound Diagnosis Atlas of Common Neck Tumors", which has certain guiding significance for the daily work of medical colleagues. He also participated in the preparation of diagnosis and treatment guidelines such as "Expert Consensus on Several Common Clinical Issues in Breast Ultrasound (2018 Edition)", "Expert Consensus on Several Common Clinical Issues in Ultrasound of Thyroid and Related Cervical Lymph Nodes (2018 Edition)", and "2020 Chinese Guidelines for Ultrasound Risk Stratification of Thyroid Nodules: C-TIRADS". The department applied for 3 national invention patents and was approved for 1 national invention patent. The department has participated in the screening of liver tumors in Tianjin for many years, and has selected personnel to participate in the National Health Commission's technical training on ultrasonic diagnosis and treatment of breast cancer for rural women, etc., to help Tianjin's medical and health undertakings. At the same time, our department has repeatedly selected personnel to participate in assistance activities in Gannan, Gansu, Qamdu, Tibet, Luliang, Shanxi and other places to improve local medical technology. The Department of Ultrasound Diagnosis will continue to work hard to provide every patient with the highest quality diagnostic and treatment services with full enthusiasm, and will work hard to fulfill its mission based on the work of its predecessors. View full introduction

Tumor Prevention Medicine Center›

The Cancer Preventive Medicine Center of Tianjin Medical University Cancer Hospital was founded in 1977 and was named after the Breast Cancer Prevention and Treatment Group. It has been 44 years since its establishment. In 2010, the department was officially renamed the Cancer Preventive Medicine Center and became one of the first six qualified physical examination institutions of the Tianjin Municipal Health and Family Planning Commission. The department is mainly responsible for the tasks and work: carrying out disease census featuring tumor screening to ensure early detection of tumors; Through population health education, popularize cancer prevention knowledge and discover and correct bad lifestyles and habits; At the same time, we will focus on a number of scientific research projects on this basis, and will actively carry out early intervention treatments based on the research results to fundamentally prevent the occurrence of cancer. The tumor screening work carried out by the department not only covers Tianjin area, but also radiates to the surrounding provinces, municipalities and autonomous regions of Tianjin. The number of people screened annually in the department is increasing year by year. Since 2017, there have been more than 300 new cancer patients every year. A green channel has been opened to detected patients to ensure that patients receive rapid and effective treatment. In addition to tumor screening work, the department also participates in organizing or undertaking a number of special tumor screening projects, including local breast cancer screening projects with central fiscal transfer payments, and surveys on the current situation of thyroid cancer high-risk areas. It also participated in the formulation of the "Breast Cancer Screening Guidelines in China" and participated in the compilation of He has published academic monographs such as "Family Hereditary Tumor Handbook" and "Chinese Anti-Cancer Association Popular Science Guide for Early Cancer Screening", participated in the reprinting of the popular science series "How Much Do You Know About Cancer - Scientific Cancer Prevention", and the self-made science popularization leaflet "Prevention and Screening of Common Tumors" has also received good response. In terms of science popularization and scientific research, the department is also making continuous progress. In 2020, the center was approved as the "Early Cancer Screening Science Popularization Education Base" of the Chinese Anti-Cancer Association, and won 1 Elite Award and 5 Excellence Awards in the CCO Cancer Science Popularization Competition; Participated in the hospital’s official science popularization activities for many times; In 2020, he won 3 "Explanation Category Finalist Awards" in the "Healthy China-Cancer Prevention and Control Action Health Science Popularization Competition". He has presided over 2 National Natural Science Foundation projects, 2 provincial and ministerial level projects, 5 municipal bureau level projects, and 5 college level projects. Published more than 30 papers of various types, including more than 20 papers included in SCI and 5 in the Chinese series. It teaches 1 to 2 masters of oncology every year. The laboratory also undertakes the internship and teaching tasks of the laboratory major of Fenyang College of Shanxi Medical University, and participates in the training of 6 undergraduate students. The Preventive Medicine Center of Tianjin Cancer Hospital currently has a staff of 45 people, including 15 physicians, 13 nurses, and 12 technicians, including 3 doctors, 8 masters, and 26 undergraduates. The main personnel structure is oncology. It is also equipped with public health majors, epidemiology, statistics and other related professional and technical personnel, which has laid a good foundation for the smooth development of clinical and scientific research related to tumor screening. Since 2014, it has established a good cooperation and exchange relationship with the Moffitt Cancer Center in the United States, and has sent two professional and technical personnel to study abroad. At the same time, young doctors actively participate in relevant skills training in addition to their own work, and have 3 national clinical genetic counselors and 7 health managers. The main diagnostic and treatment equipment currently available in the department include: digital X-ray machine, color Doppler ultrasound, etc. The department has an independent laboratory and radiological diagnosis room, and carries out routine physical examination projects. At the same time, a "Tumor Consultation Clinic" is opened. The visiting doctors have a master's degree or above in oncology or related majors, have certain clinical experience, and have passed the national clinical genetic counselor certification or the Chinese Anti-Cancer Association's tumor genetic counseling training. They provide relatively professional guidance for groups at high risk of cancer, people with a family history of cancer, and other groups. In line with the purpose of "people-oriented", the department continuously improves early tumor diagnosis methods, standardizes tumor screening procedures, actively develops new detection methods and detection methods, and improves the early detection rate of tumors. At the same time, we focus on cancer prevention research based on health screening and actively implement the transformation of scientific research results to achieve the goal of "serving people." "Because we are professional, we are trustworthy" is the commitment made by our department. Address: 1-3F, Building E, Tianjin Cancer Hospital, North Huanhu West Road, Hexi District Sports Institute, Tianjin City Contact number: 022-23559213 View full introduction

Nutrition Department›

The Nutrition Department of Tianjin Medical University Cancer Hospital is a department specializing in nutritional diagnosis and treatment of cancer patients. Founded in 2014, Director Wang Kun leads the nutrition department team to always be patient-centered and take the development of tumor nutrition as its own responsibility, and carry out extensive work in medical treatment, teaching, and scientific research. After several years of development, the department has initially formed the disciplinary characteristics of nutritional assessment, nutritional diagnosis, and nutritional treatment. It is the first in China to carry out a home-based nutritional diagnosis and treatment model for cancer patients, and is also one of the first batch of "National Standardized Tumor Nutritional Treatment Demonstration Wards" of the China Anti-Cancer Association. The Department of Nutrition currently has 10 professionals, including 1 with senior professional titles, 2 with intermediate professional titles, and 7 with junior professional titles. A professional team including nutrition doctors, nutrition nurses, nutrition technicians, etc. has been formed. The nutrition department has a complete nutrition screening and evaluation system, and can provide individualized nutrition diagnosis and treatment plans to patients at different stages of anti-tumor treatment. For patients with nutritional and metabolic disorders, nutritional physical examination and anthropometric measurements, triceps skinfold thickness, grip strength, body composition analysis, resting energy consumption measurement, and laboratory examinations are performed to make nutritional diagnosis. Then, by determining appropriate nutrient requirements, parenteral nutrition, enteral nutrition, dietary nutrition and other treatment methods are used to adjust, and food models are used to help patients establish quantitative concepts. The nutrition clinic is responsible for the nutritional evaluation, nutritional diagnosis, and nutritional treatment of people suffering from malnutrition caused by various reasons such as diabetes, hyperlipidemia, and obesity during the perioperative period, perichemotherapy period, periradiation therapy period, and diabetes, hyperlipidemia, and obesity after discharge. The Nutrition Department has a nutritional metabolism testing room, which mainly completes nutritional assessments such as patient's anthropometry (height, weight, circumference, grip strength, skinfold thickness, etc.), nutritional physical examination, energy metabolism testing, body composition analysis, etc. It can discover malnutrition problems in cancer patients and provide basis for nutritional diagnosis and treatment. The Department of Nutrition has established an enteral nutrition preparation room, which is mainly responsible for the preparation of nutritional solutions and homogenized meals for inpatient and outpatient patients with oral insufficiency, nasogastric (intestinal) tubes, and gastrointestinal fistula patients. There are standardized SOPs, in accordance with food and drug compatibility contraindications, aseptic technology and operating specifications for preparation, and completion of the preparation of enteral nutrition solutions and oral nutritional supplements. The preparation room covers an area of ​​100m2 and is divided into four areas, including the scrubbing and disinfection area, the preparation area, the cooking area, the distribution area, etc. Each area is equipped with corresponding facilities and equipment. While completing clinical work, the department actively carries out research on nutritional metabolism, clinical diagnosis and treatment of tumor diseases, and improves the nutritional assessment system; The research results provide a basis for the formulation of nutritional diagnosis and treatment standards for cancer patients. Establish an information system for nutritional diagnosis and treatment follow-up of cancer patients to build a platform for long-term and multi-center research. Now he has undertaken 4 college-level projects and published 4 papers in the past two years, including 1 included in SCI. View full introduction

Endoscopy Department›

The Endoscopy Department of Tianjin Medical University Cancer Hospital is a tertiary-level cancer specialist hospital that integrates medicine, teaching, research and prevention. It is a national cancer medical research center. The Endoscopy Diagnosis and Treatment Department uses the hospital as a platform and is committed to tumor prevention and early diagnosis and early examination; Taking the hospital motto of "Morality and excellence in medicine" as a guide for action and the service tenet of "Serving patients with everything and relieving patients' pain", we strive to create a work team that is united and forge ahead, proactive, striving for excellence, and emphasizing both clinical and scientific research. Currently, under the leadership of Director Zhou Dejun, a doctor of surgery, the department has a total of 14 physicians, including 3 chief physicians, 1 deputy chief physician, 4 attending physicians, and 6 physicians; Among them, there are 2 doctors and 8 masters, and the department continues to recruit high-quality members to improve the knowledge and talent reserves. The current professional layout of the department is: gastroscopy room, colonoscopy room, laryngoscopy room, bronchoscopy room, endoscopic ultrasonic room, painless examination room, etc. It is equipped with 8 sets of electronic endoscope mainframes and dozens of high-definition electronic gastrointestinal scopes, electronic nasopharyngeal bronchoscopes, ultrasonic endoscopes, duodenoscopes, as well as microwave, high-frequency electrocoagulation and resection equipment and argon gas knives. In 2017, the Endoscopy Department diagnosed and treated nearly 37,000 patients every year. It not only carries out routine examinations such as gastroscopy, colonoscopy, nasopharyngolaryngoscopy, and bronchoscopy to provide clinical departments with accurate examinations, detailed reports, and important diagnosis and treatment information. In recent years, it has also carried out painless endoscopy to meet the needs of more patients. The department performs dilation, stent placement and other treatments for stenotic lesions. The department is now proficient in the placement of nutrition tubes (including percutaneous endoscopic jejunostomy PEG/PEJ, etc.), post-operative bleeding treatment of the gastrointestinal tract (injections, hemostatic clips, etc.), foreign body removal, endoscopic retrograde cholangiopancreatography (ERCP) and related treatments. The technical backbone of the department continues to delve into the business and is proficient in the diagnosis and treatment of early tumors of the gastrointestinal tract and respiratory tract. In recent years, it has carried out endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) and other procedures for the diagnosis and treatment of precancerous lesions and tumors in the gastrointestinal tract and respiratory tract, and has achieved good clinical results and unanimous praise. Since then, the department has successively carried out minimally invasive techniques such as endoscopic excision (ESE), endoscopic submucosal tunnel resection (STER), and endoscopic full-layer resection (EFR), which have achieved the expected results and significantly reduced patients' pain. The department completes more than 2,000 endoscopic ultrasound (EUS) cases every year, providing more compliant, efficient, humane and high-quality services for early diagnosis and treatment of tumors as well as palliative care for advanced patients. In 2018, the new outpatient building of Tianjin Cancer Hospital will be put into use, and the first phase of the endoscopic diagnosis and treatment center will be put into use with an area of ​​2,000 square meters. New diagnosis and treatment technologies such as Haibo knife, electromagnetic navigation, medical thoracoscopy, and bronchoscopy cryotherapy will continue to bring benefits to more patients. Here, we solemnly promise that the Endoscopy Department of Tianjin Cancer Hospital will continue to aim at the international level, strive to reach the upper reaches, and strive to build a first-class endoscopic diagnosis and treatment center in China. It will continue to take "removing human suffering and promoting the perfection of health" as its mission, and collaborate with more brother departments to assist in the diagnosis and treatment of tumor diseases and contribute to the national health cause. View full introduction

Advanced Ward›

The advanced ward of Tianjin Medical University Cancer Hospital is a comprehensive department that takes advantage of multidisciplinary expert consultation (MDT) and rapid recovery surgery, has minimally invasive surgery and comfortable nursing services as its technical expertise, and features an elegant and warm ward environment, professional and reassuring star-level services, and the provision of psychological consultation and health coaching to patients. It mainly treats cancer surgery patients. There are a total of 44 hospital beds including suites, single wards, double wards and intensive care units, with an annual operation volume of more than 500 cases. The team is jointly built by a number of professional oncologists and oncology nurses with comprehensive skills, professional proficiency, rigorous and responsible, and is committed to providing patients with a professional, full-process, humanized and comfortable high-end medical and nursing experience. Pan Yuan, director of the department, specializes in surgical and comprehensive treatment of gastrointestinal tumors, and is particularly good at minimally invasive surgical treatment of other tumors in the stomach and abdomen. He once served as a senior visiting scholar at a world-renowned cancer center and received professional training in standardized and precise cancer treatment. He also studied minimally invasive gastric cancer surgery and comprehensive management of gastrointestinal tumors at first-class gastric cancer treatment institutions in Japan and South Korea, and completed the first laparoscopic radical gastric cancer surgery in our city. Director Qi Daliang, an experienced expert, is good at treating various thoracic tumors such as lung cancer and esophageal cancer. He is especially good at minimally invasive surgical treatment and individualized and precise treatment of such tumors, and has rich clinical experience. The hospital-wide multidisciplinary expert consultation system established in the advanced ward is an extension of the advanced MDT diagnosis and treatment model in the field of international cancer diagnosis and treatment. It serves people with high-end diagnosis and treatment needs and difficult and rare cases. An expert team composed of multidisciplinary experts in the hospital provides patients with individualized, precise and full-process diagnosis and treatment guidance at the first time. The consultation team can be composed of senior experts from imaging, pathology, surgery, internal medicine, radiotherapy, anesthesiology, ICU and other professional departments, and can invite well-known experts from other top tertiary hospitals in our city to participate in the consultation at any time according to the needs of the patient's condition. While providing professional, high-quality, individualized diagnosis and treatment guidance, it eliminates the "ineffective" links in the previous medical treatment process, improves medical treatment efficiency, and improves the quality of diagnosis and treatment. The concept of rapid recovery surgery is a major innovation in the field of modern surgery. It is a general term for a series of preoperative, intraoperative and postoperative technical links aimed at reducing iatrogenic trauma caused by surgery, alleviating patient pain, and accelerating the recovery process. The advanced ward introduced and practiced this technology earlier in our city. It now has a technically mature medical and nursing implementation team, and the enrollment rate of surgical cases exceeds 80%. Combined with minimally invasive surgery, it reduces the pain caused by surgery to patients, shortens postoperative recovery time, and completely improves the medical experience and physical and mental status of surgical patients. In order to improve patients' compliance with treatment and reduce their psychological burden and fear, the advanced ward provides effective psychological intervention to admitted patients. Our department cooperates with the Psychology Teaching and Research Office of Tianjin Normal University to train clinicians in psychological counseling skills and work together to provide patients with psychological counseling and treatment. It effectively solves the various problems and worries faced by patients and their families about the disease, opens their "heart knots", and allows patients to face the disease correctly, participate in treatment optimistically, and actively fight against the disease. The senior ward has first-class star-rated services and is highly praised by patients and their families. The department has an excellent nursing team. All members of the nursing department adhere to the nursing concept of "humanistic care and friendly service" in their work, insist on learning new knowledge and new technologies, constantly deepen the service concept, and strive to provide the highest quality and most dedicated services, so that patients can rest at ease and actively receive treatment in the warmest and most considerate environment. The Nursing Department of this department won the title of "National Youth Civilization" in 1999 and has maintained it to this day. Since Tianjin Cancer Hospital launched the "Star Service" selection in the whole hospital, the high-end ward has been awarded the honorary title of "Three-Star Department" of the hospital. The advanced ward of Tianjin Cancer Hospital, positioned as a first-class department in the country, not only improves medical work, but also has an active academic atmosphere. Academic exchange activities are held every week in the department to supervise medical staff to obtain cutting-edge medical knowledge. The department selects doctors every year to participate in large-scale oncology academic conferences at home and abroad to exchange information and actively follow up on the latest advances in cancer treatment. At present, the department undertakes several national and municipal scientific research projects, publishes several SCI and core journal papers every year, and scientific work and clinical work go hand in hand. View full introduction

Breast Regeneration›

The Breast Reconstruction Department of Tianjin Medical University Cancer Hospital is a breast tumor surgery department featuring breast reconstruction. The department not only carries out various radical surgeries for breast cancer and comprehensive treatments for breast cancer, but also carries out breast reconstruction surgeries according to the needs of patients. The department currently has 10 doctors, including 2 senior doctors, 2 deputy senior doctors, and 6 junior and intermediate doctors. Since its establishment, the department has carried out standardized diagnosis and treatment of breast cancer with reference to international guidelines, and has carried out radical surgery, breast-conserving surgery, sentinel lymph node biopsy and other surgeries as well as comprehensive perioperative treatment. The treatment level is in sync with the international level. As one of the earliest teams in China to carry out immediate breast reconstruction after breast cancer surgery, our department has completed more than 1,500 breast reconstruction surgeries since Professor Zhang Xuehui presided over the completion of the first pedicled TRAM flap breast reconstruction in 2001. The successful implementation of free flap breast reconstruction surgery marks that our department’s breast reconstruction technology reaches the international level. The immediate breast reconstruction performed by our department allows breast cancer patients to avoid the pain of breast loss while receiving standard radical breast cancer surgery and standardized treatment; Delayed breast reconstruction allows patients who have undergone mastectomy to restore the perfect breast curve, rebuild patients' confidence, and truly realize the treatment model of biopsychosocial medicine. 1. Discipline characteristics and new technology development Discipline Features: Provide comprehensive treatment for breast cancer patients, focusing on oncology surgery and featuring oncoplastic surgery. Recently developed new technologies: (1) Breast patch combined with prosthetic breast reconstruction: It can avoid damage to the donor site and effectively reduce the postoperative complication rate; (2) ICG assessment and detection of skin flap blood supply: it can better observe and evaluate the blood supply of skin flaps, and effectively reduce the postoperative complication rate; (3) Autologous fat transplantation: The patient's own fat can be used to trim and reconstruct the breast shape and improve the postoperative aesthetic effect. 2. Talent, scientific research development and construction Since 2001, it has successfully hosted 9 national breast reconstruction study classes after breast cancer surgery, with nearly a thousand participants, making certain contributions to the popularization and promotion of breast reconstruction work in China. Members of the department currently host 2 National Natural Science Foundation projects, 1 provincial scientific research project, and host or participate in multiple clinical trials. View full introduction

Diagnostic Breast Imaging›

The Breast Imaging Diagnostic Department of Tianjin Medical University Cancer Hospital was established at the end of 2009. It is a professional department integrating mammography, ultrasound, magnetic resonance examination and diagnostic projects. Currently, commonly used examination methods for breast imaging include X-ray, ultrasound, magnetic resonance examination, etc. Among them, X-ray photography and ultrasound are the main examination methods. The combination of the two is currently a widely used examination method in the world. Magnetic resonance examination has become an important supplementary method to X-ray and ultrasonic examination because of its imaging advantages. The three examination methods of mammography, ultrasound, and magnetic resonance are combined with each other. On the one hand, they can complement each other's advantages in various imaging examinations and achieve the purpose of early and accurate diagnosis; On the other hand, the integration of breast imaging diagnosis also makes it easier for breast patients to seek medical treatment. Breast imaging examination items that were originally divided into different departments can be completed in one department. Currently, the Breast Imaging Diagnostic Department has 2 fully digital mammography machines and 9 ultrasound machines, which technically covers mammography, ultrasound and magnetic resonance imaging diagnosis and interventional diagnosis and treatment. In addition to routine clinical work, the Breast Imaging Diagnostic Department also carries out image-guided diagnosis and treatment, such as X-ray or ultrasound-guided breast lesion positioning for clinically unreachable lesions, digital mammography-guided vacuum-assisted rotational biopsy, breast duct angiography, interventional treatment of breast lesions such as sclerotherapy of cysts, catheter drainage, puncture and fluid extraction. Our hospital's breast magnetic resonance examination work was carried out earlier in the country. The examination technology is standardized and the diagnostic accuracy is high. In particular, the "second eye" ultrasound positioning and biopsy technology guided by magnetic resonance for lesions that are not obvious on clinical palpation, X-ray and ultrasound have been recognized by domestic peers. At present, the clinical work of breast imaging diagnosis is at the leading level in China, and a large number of training doctors come to the department every year to study. In addition to clinical imaging diagnosis, the Department of Breast Imaging Diagnosis is also responsible for scientific research and teaching. Over the years, it has been responsible for the compilation of breast imaging chapters in national clinical and imaging professional textbooks, and the teaching of undergraduate, graduate and advanced courses. He has edited and co-edited several monographs on breast imaging diagnosis. The team of breast imaging diagnostic department now includes 2 senior professional technicians, 3 deputy senior professional technicians, 10 intermediate professional technicians, and 14 junior professional technicians. The training direction of the Breast Imaging Diagnostic Department for each young doctor is to master various breast imaging diagnostic technologies in an all-round way, including mammography, ultrasound and magnetic resonance diagnostic skills, so that the combined and complementary advantages of various breast imaging examination methods can be fully brought into play, and accurate and reliable imaging information can be provided for the formulation of truly individualized clinical treatment plans. The department conducts X-ray, ultrasound, and magnetic resonance imaging consultations every week, and discusses and analyzes some difficult cases; Regularly organize academic activities to cultivate and improve each doctor's clinical and scientific research ideas. The Breast Imaging Diagnostic Department has an excellent team of mammography technicians who are proficient in technical quality control. They evaluate breast phantom images every week, conduct equipment visibility inspections every month, conduct re-film analysis every quarter, and conduct compression plate pressure tests every six months and other quality control projects. The development direction of the department is to develop in all aspects of medical treatment, teaching and scientific research, supported by equipment, experts, technology and services, to benefit the majority of breast disease patients. View full introduction

Cardiopulmonary function room›

The cardiopulmonary function room of Tianjin Medical University Cancer Hospital was founded in October 1990 and was formed by the merger of the electrocardiogram room and the pulmonary function room affiliated with the Department of Chest. After twenty years of innovation and development, under the leadership of the department director Chen Qing, the department has grown from small to large, from weak to strong, and has gradually become an indispensable diagnostic department for various clinical departments. Whether it is the introduction of highly educated and qualified personnel, the development of new projects, or the rapid increase in workload, our changes are obvious to all. In 2013, it was rated as a five-star department. The cardiopulmonary function department was officially renamed as the cardiopulmonary function department and promoted to a first-level department. It has been rated as an excellent department in the hospital many times. The department has gradually developed and currently covers the following diagnostic items: twelve-lead electrocardiogram, propranolol test, atropine test, 24-hour dynamic electrocardiogram detection system, 24-hour ambulatory blood pressure detection system, and dynamic electrocardiogram and blood pressure two-in-one detection system. Pulmonary function testing includes: ventilation function measurement, diffusion function measurement (rebreathing method, one-breath method), residual function measurement, and pulse oscillation pulmonary resistance measurement. Equipment in the department: 4 electrocardiographs: one Optoelectronic 9130, one Marquette 1200, one Foton 4010, and one Bangjian 9801. There are three ambulatory ECG PI analysis systems, 51 24-hour ambulatory ECG recorders (including 2 button-type ambulatory ECG recorders), two ambulatory blood pressure monitoring recorders, 2 ambulatory ECG and blood pressure two-in-one recorders, and two Jaeger pulmonary function meters with IOS. In view of the limitations of the cardiopulmonary system diseases in the cancer hospital and the lack of support from the respiratory heart ward, this department is based on the comprehensive assessment of the cardiopulmonary function of cancer patients, in order to cooperate with the corresponding invasive and non-invasive treatments for cancer patients, and to reduce the occurrence of injuries, complications and accidents as the direction and feature of the discipline construction. There are currently 12 members in the department, including 1 deputy chief physician, 3 attending physicians, 3 supervisory nurses and 4 physicians. Since the establishment of the department, talents have been gradually introduced, and the staff's academic qualifications have gradually improved. Currently, there are 5 master's degree students, and they have been trained and studied separately. They have participated in multiple national high-level ECG trainings, difficult ECG seminars, short-term pulmonary function training courses, and Tianjin ECG consultation and ECG reading competitions. They have also participated in national difficult ECG seminars, listened to a series of high-level lectures, and hired experts from other hospitals to give many lectures, so that the diagnostic level can keep up with the pace of general hospitals and cardiovascular specialty hospitals. In terms of scientific research and development, he has the courage to innovate and persists in research. In the past two years, he has published 4 articles related to cardiopulmonary function assessment during surgery. He has completed the hospital-level project "Comprehensive Assessment of the Risk of Respiratory and Circulatory System Complications after Radical Resection of Lung Cancer with Multiple Indicators of Cardiopulmonary Function" and developed a mathematical model for assessment, which has paved the way for the future integration of the two disciplines. Another special project "Study on the role of TOP2β/UCO2 pathway in doxorubicin-induced cardiotoxicity" is ongoing in order to further understand the cardiotoxic mechanism of chemotherapy drugs. In the past two years, the undergraduate department has published four SCI articles, with the highest impact factor of 5.168, and accumulated 3 college-level projects. Under the high pressure of the annual workload of more than 90,000 electrocardiograms, more than 9,000 dynamic electrocardiograms, more than 1,000 drug trials, more than 15,000 pulmonary function tests, and hundreds of ambulatory blood pressure tests, not a single error or dispute occurred. The general practitioners are motivated and enterprising, constantly improving to meet the challenges of higher medical quality, diagnostic level, and scientific research technology, and ensuring the smooth work of tumor treatment. View full introduction

Nursing Department›

The Nursing Department of Tianjin Medical University Cancer Hospital is composed of a group of medical staff with rich clinical experience and professional titles of nurses or above. The Nursing Department is responsible for the hospital's nursing quality, business and technical management, and the training and management of nursing staff. It has a distribution center and a customer service center to increase clinical support and provide patients with one-stop, all-round, humanized, convenient and thoughtful services. The Nursing Department has always adhered to the service concept of "everything is patient-centered", carried out in-depth "Quality Nursing Service Demonstration Project" activities, constantly updated management concepts, strengthened the construction of the nursing team, improved the quality of nursing, ensured patient safety, and continuously improved the level of nursing services. View full introduction